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ABSTRACT
	
  
CELLULAR MECHANISMS AND NEURAL CONTROL OF SODIUM APPETITE IN MALE RATS

Laura Ann Grafe
Dr. Loretta M. Flanagan-Cato

Sodium appetite is a reliable and robust behavior displayed by a broad range of
species. Despite its key role in survival, the biological basis of this behavior remains
undefined. The goal of this thesis is to elucidate the cellular signaling and neural
circuitry underlying sodium appetite. More specifically, I focus on the central actions of
the hormones aldosterone and Angiotensin II (AngII) in eliciting this crucial ingestive
behavior. First, I tested the hypothesis that a signaling protein downstream of the AngII
receptor, Mitogen Activated Protein Kinase (MAPK), underlies sodium appetite induced
by endogenous AngII. I demonstrated through both behavioral pharmacology and
protein expression that sodium appetite requires MAPK activation but thirst does not.
Next, I tested the hypothesis that aldosterone and AngII potentiate sodium appetite
through inactivation of an inhibitory signal.

Using functional neuroanatomy and

reversible lesions, I revealed that behavioral cooperativity between aldosterone and
AngII involves the alleviation of an inhibitory oxytocin signal relayed from the
paraventricular nucleus of the hypothalamus to the organum vasculosum lateral
terminalis. Finally, I tested the hypothesis that an increase in motivation for sodium is
associated with an increase in mesolimbic dopamine activity. Using a progressive ratio
schedule of reinforcement and functional neuroanatomy, I discovered that the
combination of AngII and aldosterone induces a selective drive for sodium, which is
associated with an increase in neural activity and markers of dopamine synthesis in the
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ventral tegmental area and nucleus accumbens. Together, these findings demonstrate
that MAPK signaling is important for AngII-induced sodium appetite, and potentiation of
sodium appetite by aldosterone plus AngII requires both inhibition of oxytocin secretion
and activation of downstream mesolimbic circuitry.
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CHAPTER 1: INTRODUCTION

The goal of this dissertation is to better understand the cellular signaling and
neural circuitry underlying sodium appetite. First described by Curt Richter in 1936, this
motivated behavioral state drives animals to consume sodium in response to a sodium
deficiency. Moreover, Richter discovered that removal of the adrenal gland caused an
increase in sodium intake, and when sodium solutions were removed, rats died within
five days (Richter, 1936). The importance of this behavior was further demonstrated in
a subsequent case study of a child with an insatiable sodium appetite, which kept him
alive until a low sodium diet at the hospital resulted in his death (Wilkins & Richter,
1940). Though sodium appetite is critical for survival, key aspects of the biological basis
of this behavior remain unclear.
Scientific laboratories have designed several ways to induce sodium appetite so
that we may study its etiology. These preparations include a sodium deficient diet,
subcutaneous injection of mineralocorticoids, furosemide diuresis, and central
administration of AngII (Wolf, McGovern, & Dicara, 1974). Each of these preparations
differ in terms of time course for the development of sodium appetite and type of fluid
balance disturbance. For example, a sodium deficient diet must be administered to rats
for over a week in order to induce an observable sodium intake (Fregly, Harper, &
Radford,

1965).

A

low

dose

treatment

with

a

mineralocorticoid,

such

as

deoxycorticosterone acetate (DOC), is slightly faster, inducing sodium appetite in a
three-day period. Furosemide diuresis, which causes excretion of sodium through the
kidney, only takes about 24 hours to induce sodium intake (Jalowiec, 1974). However,
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central AngII has the most rapid effects, stimulating sodium intake within minutes
(Buggy & Jonklaas, 1984).
In this dissertation, I use two different preparations of sodium appetite, one
causing a rapid increase in central AngII, and the other using both mineralocorticoid
pretreatment and central AngII, to study the cellular mechanisms and neural control of
sodium appetite.

I first focus on cellular signals, namely mitogen-activated protein

kinase and inositol trisphosphate, in contributing to this behavior. I then use functional
neuroanatomy and reversible lesions to identify important brain areas involved in the
control of sodium appetite, focusing on initial targets like circumventricular organs and
moving towards downstream areas such as the mesolimbic dopamine system.
This introductory chapter describes our current understanding of the biological
basis of sodium appetite and some key aspects that still remain unclear. This includes a
general discussion of fluid balance, the hormone systems that control sodium appetite,
and both the neural circuitry and cellular players known to underlie this behavior.
Finally, I will present novel questions that form the basis of my dissertation research.

Fluid Balance
The human body consists of sixty percent water (Abbott, 1946). One third of this
water is contained in the extracellular fluid. Organisms precisely maintain the ratio of
water compared to electrolytes such as sodium to maintain sufficient extracellular fluids,
a process called fluid homeostasis (Jones & Bellamy, 1964). Many systems in the body
coordinate body fluid status, including the kidney, cardiovascular system, central
nervous system, and adrenal glands (Denton, McKinley, & Weisinger, 1996). Disruption
2	
  	
  
	
  

of sodium balance can have severe consequences such as high blood pressure, heart
failure, and even death (McKelvie, 2011).
Fluid disturbances are detected by both the kidney and stretch sensitive
receptors in the atria, aorta, and carotid (Folkow, 1971). The kidney regulates the
composition of extracellular fluid by selectively filtering water and sodium for excretion
(Bradbury, 1973). Substrates to be conserved are reabsorbed into the plasma, while
any remaining fluid is excreted into urine (Berne & Levy, 1988). Fluid perturbations
affect vascular stretch receptors by altering neural firing via the glossopharyngeal or
vagus nerve to the nucleus of the solitary tract and area postrema in the hindbrain
(Johnson & Thunhorst, 1997). These brain areas then release hormones that correct
fluid balance. For example, the hormones aldosterone and vasopressin are released in
fluid deficiency to cause renal reabsorption of sodium and water, respectively. Neural
control of renal blood flow can be achieved by release of noripenephrine on sympathetic
nerve terminals, as juxtaglomerular cells in the kidney have adrenergic receptors (Gill,
1979). Stimulation of renal nerves induces sodium and water retention; denervation
results in natriuresis and diuresis (Berne & Levy, 1988).
Though physiological responses aim to restore fluid homeostasis, minimizing
fluid loss is often not sufficient to reestablish balance. In this case, ingestive behavior is
required to replace the fluid lost (Johnson & Thunhorst, 1997). Cellular dehydration
occurs when sodium concentration extracellularly increases (drawing water from the
cell), or when extracellular fluid volume decreases; these situations induce osmotic thirst
and hypovolemic thirst, respectively (Almli, 1970). Osmotic thirst only requires water
intake, while hypovolemic thirst requires both water and sodium intake (Daniels, Yee, &
Fluharty, 2007). Osmotic control takes precedence over volumetric control in the body;
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there are inhibitory signals to prevent sodium appetite until osmosensors detect dilute
fluid. This may explain why sodium appetite is delayed compared to thirst (Avrith &
Fitzsimons, 1980). Without these ingestive behaviors to replace fluid lost, death would
ensue. Despite the criticality of this behavior, the biological basis of sodium appetite
remains unclear.

The Link Between Sodium Intake and Hypertension
Humans are genetically programmed to ingest approximately 0.25 grams of
sodium a day, but the average salt intake in most countries is roughly 10 grams per day
(He & MacGregor, 2010). As previously mentioned, a major function of the kidney is to
excrete excess sodium consumed. However, excreting such a large amount of sodium
is sometimes difficult, especially as one ages (Alderman, 2000). Epidemiological studies
have shown that societies with access to an abundance of sodium have higher blood
pressure than populations that do not (He & MacGregor, 2010). Not only this, but
several additional studies show that on average, high sodium intake is linked to an
increased blood pressure, which is then a risk factor for stroke and heart attack (Mann,
2013). Clinical trials have also shown that reducing sodium intake decreases blood
pressure (Vollmer et al., 2001).
Skepticism remains about whether lowering sodium intake over time in
normotensive humans will decrease the risk for hypertension, as there is some
conflicting data from previous studies (Midgley, Matthew, Greenwood, & Logan, 1996).
However, this is mostly due to poorly controlled studies that examine people with high
and low sodium intake, rather than having long-term trial where subjects restrict their
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sodium intake (Mann, 2013). In the end, it cannot be denied that there is a link between
high sodium intake and hypertension, and it should not be neglected.
understanding

the

biological

underpinnings

of

sodium

appetite may

Better
help

in

characterizing the link between this critical behavior and hypertension.

The Renin-Angiotensin-Aldosterone System (RAAS)
It took decades for scientists to make progress in understanding how Richter’s
adrenalectomy experiments induced such robust sodium appetite.

These studies

revealed that adrenal steroids, such as aldosterone, were responsible for this behavior
(Wolf, 1965). The contributions of another hormone, Angiotensin II, were much later
determined to be important for sodium appetite as well

(Buggy & Jonklaas, 1984).

These hormones are part of the Renin-Angiotensin-Aldosterone System (RAAS), which,
as one might guess, is essential for sodium balance (Reid, 1985). Detection of low
blood volume or pressure stimulates RAAS both peripherally and centrally (Denton et al.,
1996).

The actions produced by RAAS reestablish homeostasis and are thereby

necessary for survival (Fitzsimons, 1998).
	
  
Peripheral RAAS
When blood pressure is low, an enzyme called renin is released from stretchsensitive juxtaglomerular cells in the kidney (Reid, 1985). Renin converts a precursor
hormone called angiotensinogen, concentrated in the liver, to Angiotensin I (Peach,
1977). Angiotensin I is converted by Angiotensin Converting Enzyme (ACE), secreted
by the lung, to Angiotensin II (AngII).
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Upon activation, AngII increases blood pressure to normal levels through several
avenues. Peripherally, AngII causes vasoconstriction, including contraction of the renal
smooth muscle, altering renal blood flow and glomerular flitration to reabsorb more fluids
(Berne & Levy, 1988). Additionally, AngII induces the release of aldosterone from the
adrenal gland, which then reabsorbs sodium in the kidney, thereby retaining more fluid
(Andersson, 1977). Aldosterone achieves this feat by increasing proteins on the
membrane that enhance the permeability of sodium so it is more readily absorbed
(Berne & Levy, 1988). In both cases, more fluid is retained, exerting more force on the
vasculature and thereby supporting blood pressure.

Central RAAS
In addition to its existence in the periphery, there is also a central RAAS (Wright
et al., 1984). However, a single brain cell that expresses all of the components of RAAS
has not yet been found; formation of active AngII in the brain may require multiple cell
interactions (Bader, 2010).

Previous studies have revealed that manipulation of

peripheral RAAS with dexamethasone does not affect central RAAS, underscoring their
independence (Ganong, 1984).

Nevertheless, brain RAAS is not completely

independent from the periphery, as AngII generated in the body can gain access to the
brain in areas with an incomplete blood brain barrier (Fitzsimons & Stricker, 1971).
Centrally, AngII stimulates vasopressin and oxytocin release, sympathetic
activation, and both thirst and sodium appetite (Reid, 1984). Vasopressin stimulates
water reabsorption in the kidney during hypovolemia, while oxytocin maintains osmotic
balance by inducing natriuresis and inhibiting sodium appetite
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(Cross & Wakerley,

1977).

AngII facilitates sympathetic activation in the autonomic nervous system by

inducing norepinephrine release (Ganong, 1984). While the onset of AngII-induced thirst
is immediate, sodium appetite it delayed; however, sodium intake is not secondary to
increased water intake

(Avrith & Fitzsimons, 1980).

Studies of transgenic mice

complement those of central administration of the neuropeptide: while mice with
increased AngII expression become hypertensive, those with reduced AngII synthesis
have decreased blood pressure, vasopressin secretion, and sympathetic activity (Bader,
2010). Together, these physiological and behavioral responses induced by central AngII
restore body fluid balance.
In addition to AngII as a critical effector of central RAAS, aldosterone plays an
important role in both blood pressure regulation and sodium appetite (Wolf, 1964).
Similar to AngII, there is some evidence of aldosterone synthesis in the brain, but the
majority of this hormone is made peripherally (Gomez-Sanchez et al., 1997). Indeed,
the absence of peripheral aldosterone induces a robust sodium appetite, as revealed by
studies in adrenalectomized rats with the inability to retain sodium (Richter, 1936).
However, a high dose of mineralocorticoids, allowing central action, also stimulates
ingestion of large volumes of sodium (Rice & Richter, 1943). Much after scientists
discovered AngII and aldosterone were separately important for sodium appetite, a study
revealed that the combination of both hormones potentiates sodium appetite but not
thirst (Fluharty & Epstein, 1983). This phenomenon has been observed in rats, pigeons
and baboons and is not secondary to natriuresis or diuresis (Fluharty & Epstein, 1983;
Massi & Epstein, 1990; Shade et al., 2002). However, it is thirty years later, and the
mechanism by which this potentiation occurs still remains unknown.
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Neural Circuitry Underlying Sodium Appetite
Neuroanatomical tract tracing and functional mapping methods have implicated
numerous brain structures involved in sodium appetite.

This neural network allows

visceral information reflecting fluid balance to be distributed into several loci that then act
as neural and endocrine ports of access into the brain (Johnson & Thunhorst, 1997).
There is a long list of brain structures, and consequently, many neurotransmitters that
are thought to be involved in the circuitry underlying this behavior including
norepinephrine, GABA, glutamate, and acetylcholine (Barnes, DeWeese, & Andresen,
2003; Dendorfer, Raasch, Tempel, & Dominiak, 1998; Oz, Yang, O'donovan, & Renaud,
2005; Ozaki, Soya, Nakamura, Matsumoto, & Ueta, 2004). Below, I will discuss brain
regions thought to be important for AngII action, aldosterone action, and where these
two hormones may interact in the brain to potentiate sodium appetite.

Brain Sites of AngII Action in Sodium Appetite
Peripheral AngII gains access to the brain by way of circumventricular organs,
namely the subfornical organ (SFO) and organum vasculosum lateral terminalis (OVLT),
which are brain regions with an incomplete blood brain barrier (Ganong, 1984). In these
circumventricular organs, two major activities contributing to fluid balance take place: 1)
plasma sodium levels are sensed through a specific sodium channel and 2) AngII binds
to its receptor; information concerning the current fluid status is then passed to other key
brain areas (Weisinger et al., 1996). Not only do these circumventricular organs contain
osmosensors themselves, but they likely receive input from other osmosensors in the
body (Johnson & Thunhorst, 1997). The OVLT also receives afferent inputs from the
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SFO and hypothalamus and projects to several hypothalamic and extrahypothalamic
areas (Camacho & Phillips, 1981).
In addition to acting as a hormone, AngII may be released from axon terminals
(Ferguson, Washburn, & Latchford, 2001).

Studies that lesioned axon terminals

projecting from the SFO to the OVLT abolished drinking, which may support a
neurotransmitter-like role for AngII

(Eng & Miselis, 1981).

Moreover, early studies

demonstrated that ablation of the SFO itself decreases water intake

(Simpson &

Routtenberg, 1973), while lesions in the OVLT abrogate sodium intake (Fitzsimons,
1980). Contrarily, infusion of AngII into the SFO induces water intake, while AngII into
the OVLT induces both water and sodium intake (Fitts & Masson, 1990). However,
more recent studies indicate that both circumventricular organs are important for sodium
appetite

(Fitts, Freece, Van Bebber, Zierath, & Bassett, 2004).

In order for these

circumventricular organs to contribute to drinking behavior, they must project to higher
order brain areas.
Besides its efferent projections to the OVLT, the SFO is known to have fibers
terminating in the paraventricular (PVN) and supraoptic nuclei (SON) of the
hypothalamus (McKinley, Badoer, & Oldfield, 1992; Miselis, 1981). The magnocellular
neurons of these hypothalamic nuclei mediate AngII-induced oxytocin and vasopressin
release

(Bisset, Clark, & Errington, 1971).

The parvocellular neurons in the PVN,

however, are responsible for sending projections to autonomic centers in the brainstem
and spinal cord

(Sofroniew, Weindl, Schrell, & Wetzstein, 1981).

Studies that

electrolytically lesioned the hypothalamus eliminated sodium appetite, demonstrating the
importance of this part of the forebrain in exhibiting this behavior (Wolf, 1967).
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Tracing and lesion experiments have highlighted the lateral hypothalamus as an
important part of AngII-induced sodium appetite circuitry. As mentioned previously, the
OVLT projects to many hypothalamic areas, including the lateral hypothalamus
(Camacho & Phillips, 1981). Experiments that lesion the lateral hypothalamus report
complete abrogation of sodium appetite, demonstrating its vital role in this behavior
(Wolf, 1964; Wolf, 1967). Recent tracing studies have revealed that particular
orexinergic neurons in the lateral hypothalamus project to the ventral tegmental area,
known to be involved in motivation (Fadel & Deutch, 2002; Narita et al., 2006). It is well
established that dopaminergic neurons in the ventral tegmental area project to the
nucleus accumbens, which then projects to the ventral pallidum to generate goal
directed movement (Carelli, 2002).

These possible connections to the mesolimbic

dopamine system suggest that sodium appetite is a motivational-affective state rather
than just a reflexive activation of motor behavior.

Brain Sites of Aldosterone Action in Sodium Appetite
The major site of aldosterone action in the brain is the nucleus of the solitary tract
(NTS) in the hindbrain (Geerling & Loewy, 2009). This brain area contains both the
mineralocorticoid receptor (MR), a steroid receptor to which aldosterone binds, and the
enzyme hydroxysteroid dehydrogenase (HSD2), which inactivates glucocorticoids and
prevents them from binding to MRs (de Kloet et al., 2000; Geerling, Kawata, & Loewy,
2006; Geerling & Loewy, 2009; Riftina, Angulo, Pompei, & McEwen, 1995).

As

glucocorticoids are much higher in concentration than aldosterone in the brain, and have
high affinity for MR, HSD2 is necessary to allow aldosterone action
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(Anderson &

Fanestil, 1976). However, HSD2 neurons are more than just aldosterone sensors, as
they are activated by prolonged sodium deficiency even after adrenalectomy (Geerling
et al., 2006; Geerling, Chimenti, & Loewy, 2008).
When an animal is sodium-deficient, the HSD2 neurons in the NTS fire,
indicating a need for sodium (J. Lu, Sherman, Devor, & Saper, 2006; Shekhtman,
Geerling, & Loewy, 2007). Moreover, the rostral NTS receives gustatory input via the
chorda tympani, allowing for sodium detection and taste (Geerling et al., 2006). The
sodium need and detection signals are integrated in the forebrain, namely, in the central
amygdala and bed nucleus of the stria terminalis (BNST). Lesions in either brain region
decrease sodium intake but not thirst (Zardetto-Smith, Beltz, & Johnson, 1994). These
integration sites then project to motor pattern generators that lead to sodium appetite.
After some consumption, post ingestive signals from the gut are received by non-HSD2
neurons in the NTS to signal the brain to stop ingesting salt (Schwartz, Woods, Porte,
Seeley, & Baskin, 2000). The direct connections in these circuits still remain unclear.

Intersection of AngII and Aldosterone Circuits in Sodium Appetite
After examining the brain areas for AngII and aldosterone action, it appears that
these hormones have separate initial targets in the brain. It has been proposed that
behavioral cooperativity of AngII and aldosterone on sodium ingestion may be based on
disinhibition (Stricker & Verbalis, 1996). In particular, AngII acts centrally to excite
oxytocin neurons, promoting hormone release from the neurohypophysis. Concomitant
central release of oxytocin inhibits sodium appetite (McKinley, Allen, Burns, Colvill, &
Oldfield, 1998).
	
  

Conversely, physiological conditions that diminish oxytocin activity
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increase sodium appetite

(Stricker & Verbalis, 1987).

Of particular relevance,

deoxycorticosterone acetate (DOC), a precursor of aldosterone, reduces AngII-induced
activation of the oxytocin neurons in the PVN and SON (Roesch, Blackburn-Munro, &
Verbalis, 2001; Stricker & Verbalis, 1996; Stricker & Verbalis, 2004). The BNST is a
candidate for integration of this information, as its GABAergic neurons that receive input
from the NTS project to the PVN, allowing for inhibition of oxytocin (Cullinan, Herman, &
Watson, 1993; Dong, Petrovich, Watts, & Swanson, 2001).

However, it remains

unknown where in the brain sodium appetite is inhibited by oxytocin.
Other brain regions, like the central nucleus of the amygdala and lateral
hypothalamus, are also thought to be important areas for integration of information
between aldosterone and AngII. Both brain regions are heavily interconnected with the
BNST, and as mentioned before, also have an established role in sodium intake
(Johnson, de Olmos, Pastuskovas, Zardetto-Smith, & Vivas, 1999; Wolf, 1967). The
central amygdala is heavily innervated by inputs from the NTS, and may influence
ingestive behaviors by its output to forebrain sites that regulate motor activity
(Bourgeais, Gauriau, & Bernard, 2001). Oppositely, the lateral hypothalamus may
receive information directly from the OVLT, which then may project to the NTS,
influencing sodium appetite (Kelly & Watts, 1996; Kelly & Watts, 1998).
The ultimate goal is to delineate the complete circuit responsible for sodium
appetite, beginning with primary input sites, and ending with motor output channels in
the brainstem and spinal cord. While many pieces of the puzzle still remain, many areas
of importance have been highlighted. But, within each brain area lie specific receptors to
which each hormone must bind, and even more complicated downstream signals at
work underlying this fascinating behavior.
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Cellular Signaling Underlying Sodium Appetite
The initial brain targets discussed above are important for AngII and aldosterone
action because they contain receptors to which these hormones can bind. It is through
actions on their respective receptors that AngII and aldosterone induce signaling
cascades, which can affect neural excitability and plasticity, thereby altering
neurotransmission in these complex circuits. Below, I will discuss signaling pathways
thought to be important for AngII action, aldosterone action, and how these two
hormones may use cellular signals to potentiate sodium appetite.

Angiotensin II Receptors
AngII acts on two different highly specific receptors, termed Angiotensin Type 1
(AT1) and Angiotensin Type 2 (AT2) receptors
Sharpe, 1973).

(Swanson, Marshall, Needleman, &

AT1 receptors are expressed on all of the brain areas previously

discussed for AngII action, while AT2 receptors decline in expression after development
and are restricted to regions involved in motor and sensory control (Reagan et al., 1994;
Gallinat, Busche, Raizada, & Sumners, 2000). While AT1 receptors mediate the actions
of AngII on blood pressure, the secretion of oxytocin and vasopressin, and water and
sodium intake, AT2 receptors are implicated in apoptosis and antagonistic roles to AT1
receptors (McKinley et al., 1996; Sugaya et al., 1995).

Expectedly, the signaling

underlying these receptors oppose one another (Huang, Richards, & Sumners, 1996).
As the AT1 receptor is involved in our behavior of interest, namely sodium appetite, we
focused on the downstream signaling of this specific receptor subtype.
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The AT1 receptor belongs to the super family of G protein coupled receptors and
associates with Gq to stimulate inositol 1,4,5-triphosphate (IP3) production and Ca2+
mobilization (Beresford MJ, 1992; Enjalbert et al., 1986). Consequently, AT1 receptor
activation increases calcium currents, which increases the firing frequency of that neuron
(Sumners, Zhu, Gelband, & Posner, 1996). In vitro research uncovered a parallel signal
transduction pathway that can occur without Gq coupling.

This pathway induces

phosphorylation of MAPK Kinase (MEK), which activates the p42 and p44 isoforms of
mitogen-activated protein kinase (MAPK) (Sadoshima, Qiu, Morgan, & Izumo, 1995),
also referred to as extracellular signal-regulated kinase 1 and 2. Subsequently, p44/42
MAPK generates downstream changes in cellular activity, including changes in gene
expression (Clark, Balla, Jones, & Catt, 1992; Lee, El-Shewy, Luttrell, & Luttrell, 2008;
LeHoux & Lefebvre, 2006). While many studies examining AT1R-induced p44/42 MAPK
activation were performed in vitro, p44/42 MAPK activation also occurs in the SFO and
PVN after a systemic AngII injection (Wei, Yu, Zhang, & Felder, 2009). As these AT1R
signaling molecules were detected in the brain, researchers have begun to investigate
their role in the neural actions of AngII, including sodium appetite.

Aldosterone Receptors
Aldosterone binds to the MR, a steroid receptor located primarily in the NTS, as
well as the SFO, OVLT, and amygdala (Geerling & Loewy, 2009). The MR is important
for sodium appetite, as demonstrated in studies using MR antisense oligonucleotides to
inhibit these actions (Sakai, Ma, Zhang, McEwen, & Fluharty, 1996; Xue et al., 2011).
When aldosterone binds to the MR, chaperone proteins dissociate, and the receptor
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translocates from the cytoplasm to the nucleus (Binart, Lombes, Rafestin-Oblin, &
Baulieu, 1991; Lombes, Kenouch, Souque, Farman, & Rafestin-Oblin, 1994; RafestinOblin, Farman, Cassingena, Ronco, & Vandewalle, 1993). Once in the nucleus, the MR
associates with transcription factors like AP-1 or NFκB to change the expression of
certain genes (Viengchareun et al., 2007). Conversely, the MR can have non-genomic
actions in the cytoplasm, where both ERK and IP3 signaling are induced (Dooley,
Harvey, & Thomas, 2012). Interestingly, non-genomic signaling often enhances the
genomic MR signaling, either through facilitation of nuclear translocation or synergistic
effects on the same target molecules (Grossmann & Gekle, 2009).

Crosstalk
Previous literature has demonstrated that AngII and aldosterone can mutually
enhance each other’s actions in the same cell.

For example, AngII stimulates

aldosterone production and stimulates nuclear localization of MR, whereas aldosterone
increases AngII binding, AT1R levels, ACE activity, and AngII signaling in peripheral
tissues (Harada et al., 2001; Hirono et al., 2007; Jaffe & Mendelsohn, 2005; Mazak et
al., 2004; Min et al., 2005; Ullian, Schelling, & Linas, 1992; Xiao, Puddefoot, Barker, &
Vinson, 2004; Xue et al., 2011). Centrally, DOC, a precursor of aldosterone, was found
to increase AngII sensitive neurons and receptors per neuron in the medial septum
(Thornton & Nicolaidis, 1994). Interaction of both aldosterone and AngII in the brain is
required for a robust sodium appetite; this has been confirmed by using central receptor
antagonists of the two hormones (Sakai, Nicolaidis, & Epstein, 1986). Thus, it may be

	
  

	
  
15	
  

through augmentation of central signaling that these two hormones potentiate sodium
appetite.

Novel Questions Addressed by this thesis
Numerous brain areas and signaling pathways that may be important for sodium
appetite have been examined, but the exact circuits and cascades that trigger this
behavior are still unknown. For my thesis, I have used two preparations of sodium
appetite: 1) furosemide with a low dose of captopril (an ACE inhibitor) to stimulate
endogenous AngII production and 2) low doses of DOC and AngII. Through use of
these preparations, I have studied novel questions concerning the cellular signals and
circuitry underlying sodium appetite as described below.

What signal is required for endogenous AngII-induced sodium appetite? Is this signal
unique to sodium appetite?
Administration of AngII intracerebroventricularly causes both sodium and water
intake (Epstein, Fitzsimons, & Simons, 1969). Recent studies have suggested that
divergent cellular signals downstream of the AT1 receptor can give rise to these
separable behavioral phenomena

(Daniels, Yee, Faulconbridge, & Fluharty, 2005).

More specifically, IP3 signaling underlies water intake, while MAPK signaling underlies
sodium appetite (Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009). This finding
was novel and intriguing; however, it remained unclear whether the result reflected a
normal physiological process or a pharmacological phenomenon based on exogenously
administered AngII. In Chapter 2 of this thesis, I use a preparation of endogenous AngII
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production to establish the physiological significance of AngII-induced p44/42 MAPK on
sodium appetite. In addition, I examine the contribution of AT1 receptor signaling in
another action of central AngII, namely, neurohypophysial secretion.

What signaling and circuitry underlies Aldosterone and AngII potentiation of sodium
appetite?
Aldosterone and AngII cooperate centrally to potentiate sodium appetite
(Fluharty & Epstein, 1983). However, the mechanism by which this occurs is unknown.
Studies in peripheral tissue reveal reciprocal enhancement of cellular signaling, but not
all signaling proteins thought to be involved have been thoroughly examined (King,
Harding, & Moe, 1988). In vivo studies suggest convergence of separate neural
systems. Specifically, there are some data that support the hypothesis that aldosterone
inhibits AngII-induced oxytocin secretion, thereby disinhibiting sodium appetite (Stricker
& Verbalis, 1987). However, the site of oxytocin action to inhibit sodium appetite and the
pathway by which aldosterone disinhibits oxytocin remain unknown. In Chapter 3 of this
thesis, I first investigate the role of MAPK and IP3 in aldosterone and AngII potentiation
of sodium appetite through use of pharmacological inhibitors and measures of signal
transduction.

I then examine the oxytocin disinhibition hypothesis concerning

aldosterone and AngII potentiation of sodium appetite by way of reversible lesions and
functional neuroanatomy.
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Does the Aldosterone and AngII potentiation of sodium appetite involve an increase in
mesolimbic dopamine activity?
Rats run faster down a runway to receive a sodium reward if both aldosterone
and AngII are present compared to either hormone alone, suggesting an increase in
motivation for this reinforcement (D. M. Zhang, Stellar, & Epstein, 1984). Additionally,
increases in dopamine activity have been observed in the nucleus accumbens in rats
depleted of sodium by a diuretic, a treatment that increases both aldosterone and AngII
(Roitman, Patterson, Sakai, Bernstein, & Figlewicz, 1999). While aldosterone and AngII
induce robust sodium ingestion, only the initial brain targets, and not downstream
circuitry of this behavior, have been well studied.

It is unclear if an increase in

mesolimbic activity underlies this increase in motivation for sodium induced by central
cooperation of aldosterone and AngII.

In Chapter 4 of this thesis, I first examine

motivation for sodium induced by cooperation of aldosterone and AngII using a
progressive ratio schedule of reinforcement. I then measure both neural and dopamine
activity in the ventral tegmental area and nucleus accumbens after both hormone
treatments to determine if an increase in mesolimbic activity is correlated with an
increased motivation for sodium.

The following studies aim to elucidate the cellular signaling and neuronal circuitry
involved in central aldosterone- and AngII-induced sodium appetite. This will advance
basic science knowledge by expanding our understanding of appetitive behavior that is
critical for survival. This research is also translational, given than a derangement of the
RAAS is responsible for 30 percent of hypertension cases (Mizuno et al., 1991); Patients
may live longer and healthier lives if inhibitors of sodium appetite can assist them in
reducing their salt intake.
	
  

	
  
18	
  

	
  
Fig 1.1. Locations of nuclei
in the rat brain implicated in
sodium appetite
Saggital plane of the rat brain
highlighting brain areas that
are important for AngII- and
aldosteroneinduction
of
sodium
appetite.
Abbreviations: NUACC =
Nucleus Accumbens, BNST =
bed nucleus stria terminalis,
SFO = subfornical organ,
OVLT = organum vasculosum
lateral terminalis, CEA =
central amygdala, PVN =
paraventricular nucleus of the
hypothalamus, LH = lateral
hypothalamus, VTA = ventral
tegmental area, NTS =
nucleus of the solitary tract
Fig 1.2. Cellular signaling
implicated
in
sodium
appetite
A simplified illustration showing
the cellular signaling underlying
both AngII- and aldosteroneinduced
sodium
appetite.
AngII actions on the AT1R
induces parallel IP3 and MAPK
signaling, while aldosterone
may have both non-genomic
and genomic actions on the
MR. Non-genomic MR actions
allow for possible crosstalk with
AngII
signaling
proteins.
Though it is pictured in the
same cell, it may not be.
Abbreviations: AT1R = AngII
Type 1 Receptor, MR =
Mineralocorticoid receptor.
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CHAPTER 2: ENDOGENOUS ANGIOTENSIN II-INDUCED P44/42 MITOGENACTIVATED PROTEIN KINSAE ACTIVATION MEDIATES SODIUM APPETITE BUT
NOT THIRST OR NEUROHYPOPHYSEAL SECRETION IN MALE RATS
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SUMMARY
The renin-angiotensin-aldosterone system makes a critical contribution to body
fluid homeostasis, and abnormalities in this endocrine system have been implicated in
certain forms of hypertension. The peptide hormone angiotensin II (AngII) regulates
hydromineral homeostasis and blood pressure by acting on both peripheral and brain
targets. In the brain, AngII binds to the angiotensin type 1 receptor (AT1R) to stimulate
thirst, sodium appetite and both arginine vasopressin (AVP) and oxytocin (OT) secretion.
The present work used an experimental model of endogenous AngII to examine the role
of p44/42 mitogen-activated protein kinase (MAPK) as a signaling mechanism to
mediate these responses. Animals were given a combined treatment of furosemide and
a low dose of captopril (furo/cap), a diuretic and an angiotensin converting enzyme
inhibitor, respectively, to elevate endogenous AngII levels in the brain. Furo/cap induced
p44/42 MAPK activation in key brain areas that express AT1R, and this effect was
reduced with either a centrally administered AT1R antagonist (irbesartan) or a p44/42
MAPK inhibitor (U0126). Additionally, furo/cap treatment elicited water and sodium
intake, and irbesartan markedly reduced both of these behaviors. Central injection of
U0126 markedly attenuated furo/cap-induced sodium intake but not water intake.
Furthermore, p44/42 MAPK signaling was not necessary for either furo/cap- or
exogenous AngII-induced AVP or OT release. Taken together, these results indicate
that p44/42 MAPK is required for AngII-induced sodium appetite, but not thirst or
neurohypophysial secretion.

This result may allow for discovery of more specific

downstream targets of p44/42 MAPK to curb sodium appetite, known to exacerbate
hypertension, while leaving thirst and neurohypophysial hormone secretion undisturbed.
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INTRODUCTION
The renin-angiotensin-aldosterone system promotes body fluid homeostasis by
coordinating physiological and behavioral responses to correct fluid perturbations
(Bakris, 2010; Peach, 1977). Hypotensive and hypovolemic events prompt the release
of the enzyme renin from the kidneys, which initiates a catalytic cascade that ultimately
elevates blood levels of the hormone angiotensin II (AngII) (Ferguson et al., 2001).
Peripherally, AngII constricts blood vessels to support blood pressure. Circulating AngII
binds to brain receptors in the subfornical organ (SFO) and organum vasculosum of the
lateral terminalis (OVLT), brain regions with an incomplete blood-brain barrier.

In

addition, AngII produced locally by the brain renin-angiotensin system acts on relays in
the median pre-optic nucleus (MNPO), paraventricular nucleus of the hypothalamus
(PVN) and supraoptic nucleus (SON) (Geerling & Loewy, 2008). Acting upon these
central nuclei, AngII prompts thirst, sodium appetite (Epstein, Fitzsimons, & Rolls, 1970;
Findlay & Epstein, 1980), and both arginine vasopressin (AVP) and oxytocin (OT)
secretion (Marc & Llorens-Cortes, 2011). While the physiological actions of AngII are
well known, our understanding of its cellular actions is incomplete.
The central actions of AngII are mediated by the angiotensin type 1 receptor
(AT1R), which belongs to the super family of G protein coupled receptors and associates
with Gq to trigger inositol 1,4,5-triphosphate (IP3) production and Ca2+ mobilization
(Beresford MJ, 1992; Enjalbert et al., 1986).

In vitro research uncovered a parallel

signal transduction pathway that phosphorylates MAPK Kinase (MEK), which activates
mitogen-activated protein kinase (MAPK) (Sadoshima et al., 1995) including the p42 and
p44 isoforms, also referred to as extracellular signal-regulated kinase 1 and 2. In turn,
p44/42 MAPK provokes a variety of downstream changes in cellular activity, such as
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changes in gene expression (Clark et al., 1992; Lee et al., 2008; LeHoux & Lefebvre,
2006).

Although the majority of studies examining AT1R-induced p44/42 MAPK

activation were performed in vitro, p44/42 MAPK activation also occurs in the SFO and
PVN after a systemic AngII injection (Wei et al., 2009).

As these AT1R signaling

molecules were detected in the brain, researchers have begun to investigate their role in
the neural actions of AngII.
A previous study employed signaling selective AT1R ligands and inhibitors to
reveal that the inositol triphosphate (IP3) branch of AT1R signal transduction mediates
thirst, whereas the p44/42 MAPK signaling pathway mediates sodium appetite (Daniels
D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009; Daniels D, Yee DK, Faulconbridge LF,
Fluharty SJ, 2005). This finding was novel and intriguing; however, it remained unclear
whether the result reflected a normal physiological process or a pharmacological
phenomenon based on exogenously administered AngII. Therefore, to establish the
physiological significance of AngII-induced p44/42 MAPK on sodium appetite, we
exploited a preparation for endogenous AngII-induced sodium appetite (Thunhorst &
Johnson, 1994). More specifically, a combined treatment of furosemide and a low dose
of captopril (furo/cap), a loop diuretic and an inhibitor of angiotensin converting enzyme
(ACE) inhibitor, respectively, elevates brain levels of AngII. The low dose of captopril
blocks the conversion of diuresis-provoked angiotensin I to AngII in the periphery, but
still allows conversion in circumventricular organs, which contain very high levels of ACE
in comparison to the periphery (Chai, Allen, Adam, & Mendelsohn, 1986). The high
level of endogenous AngII production in the brain elicits rapid and robust thirst and
sodium ingestion (Thunhorst, Morris, & Johnson, 1994). We used this model to test the
hypothesis that p44/42 MAPK phosphorylation mediates sodium, but not water, ingestion
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induced by endogenous AngII production.
Given the myriad actions of AngII in the brain, it is important to consider the
signaling pathways involved in other AngII-induced effects, such as neuroendocrine
responses. In addition to its effects on water and sodium ingestion, central AngII is a
potent stimulus for AVP and OT secretion (Andersson, Eriksson, Fernandez, Kolmodin,
& Oltner, 1972). While AVP promotes renal water reabsorption, OT increases renal
sodium excretion and centrally inhibits sodium appetite (Conrad, Gellai, North, & Valtin,
1993; Ganong, 1977; Stricker & Verbalis, 1996). AT1R-expressing neurones in the SFO
send axonal projections to the PVN and SON, where AVP and OT neuronal activity is
increased to promote hormone release from the neurohypophysis (McKinley et al.,
1998). We addressed the role of p44/42 MAPK signaling in AngII-induced AVP and OT
by measuring plasma levels of the neurohypophysial hormones after either furo/cap
treatment or icv AngII in the presence of an AT1R antagonist or MEK inhibitor. Overall,
our experiments better define the participation of p44/42 MAPK signaling in the
regulation of fluid balance.

MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats (n = 83) that weighed between 225-250 g were
obtained from Charles River Laboratories (Wilmington, MA, USA).

Rats were pair-

housed in plastic tubs with standard bedding and with food and water available ad
libitum, except during experimental procedures. The temperature in the colony was
maintained at 22 °C with a 12:12 h reversed light/dark cycle. Animals were allowed at
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least one week to acclimate to the colony before any procedures were performed. The
Institutional Animal Care and Use Committee of the University of Pennsylvania approved
all procedures with animals.

Drugs
Furosemide (Abbott Laboratories, N. Chicago, IL) and captopril (SQ-14225,
Bristol-Meyers-Squibb

Pharmaceutical

Research

Institute,

Princeton,

NJ)

were

administered subcutaneously (sc) at doses of 10 mg/kg and 5 mg/kg body weight,
respectively, in 0.9% sterile saline. Equal volume 0.9% sterile saline was administered in
control animals. The specific doses for each drug given intracerebroventricularly (icv)
were as follows: 20 ng AngII (Bachem, King of Prussia, PA), 0.4 ug irbesartan (a
generous gift from Dr. Sal Lucania, Bristol Myers Squibb), 2 nmol U0126 dissolved in
10% DMSO (Promega, Madison, WI). Artificial cerebrospinal fluid (aCSF; R&D Systems,
Minneapolis, MN) plus 10% DMSO was administered icv as a vehicle control.

All

injections were administered icv in a volume of 2 ul.

Surgeries
Surgeries were performed under aseptic conditions. Animals were anaesthetised
with a combination of ketamine and xylazine (70 and 5 mg/kg, respectively,
intraperitoneally [ip]) before being fixed in a stereotaxic frame and implanted with 26gauge guide cannulae (Plastics One, Roanoke, VA, USA) aimed at the lateral ventricle.
The coordinates (0.48 mm caudal to bregma, 1.6 mm from mid-line and 4.2 mm ventral
to dura mater) were chosen to allow an internal injection cannula to extend beyond the
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guide cannula into the ventricular space. The cannulae were fixed in place with dental
cement and bone screws, and the animals were allowed at least five days to recover
before verification procedures were performed. After surgery, animals were injected with
yohimbine (0.11 mg/kg, Ben Venue Laboratories Bedford, OH) and orally administered
Children’s Tylenol (30 mg/ml, McNeil PPC Inc, Fort Washington, PA). Upon awakening,
animals were singly housed.
Five days after surgery and prior to undergoing experimental treatments, animals
were tested for correct cannula placement and patency. They were given an injection of
20 ng of AngII diluted in aCSF icv via a Hamilton syringe connected with PE-10 tubing to
an injector that terminated 1 mm beyond the guide cannula. Animals were excluded
from the experiment if they failed to demonstrate a drinking response in less than 30
seconds, consuming at least 3 ml of water, in two separate AngII challenges. Animals
began testing three days after the icv test injections.

Enzyme Linked Immunosorbent Assays
Experiment 1. Animals were pretreated with either vehicle, irbesartan, or
U0126 icv. Fifteen minutes after the icv injection, they were given furosemide, sc,
followed 10 minutes later by captopril, sc. Thirty minutes after the captopril injection,
animals were rapidly decapitated without anaesthesia and the brains were flash frozen in
hexane over dry ice. Rats were not administered anaesthesia because it is known to
increase phosphorylated p44/42 MAPK levels, which would compromise our results
(Khan & Watts, 2004). Micropunches (1 mm diameter) of the brain regions of interest
(OVLT, SFO, PVN, SON, and primary somatosensory cortex) were obtained from 300	
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µm sections cut on a cryostat. OVLT/SFO and PVN/SON punches were combined from
each rat to ensure detectable levels for analysis. The micropunched tissue samples
were immersed in the lysis buffer provided in the Pathscan p44/42 MAPK Sandwich
ELISA

kit

(Cell

Signaling

Technology,

Danvers,

MA)

plus

1

mM

phenylmethanesulfonylfluoride (Sigma, St Louis, MO). The brain tissue samples were
sonicated three times for one second (incubated on ice between bursts) followed by
centrifugation at 14,000 rpm at 4°C for 10 minutes. Supernatant was collected and a
protein assay was performed on five microliters of each sample. Based on the protein
levels detected by Bicinchoninic Acid Assay, appropriate amounts of lysis buffer,
sample, and sample diluent were mixed for each sample. This mixture (100 µl) was
loaded into corresponding wells in both the Total and Phospho p44/42 MAPK Sandwich
ELISA kits. The ELISA was performed according to the protocol provided by each kit.

Behavioral Study
For behavioral experiments, rats were removed from their home cages
approximately one hour before the onset of the dark phase. The rats were weighed and
then placed in individual wire mesh-bottomed cage equipped with a funnel and
calibrated tube for the collection of urine, and with two 25-ml bottles available for
drinking tap water and 1.5% saline, each marked with 0.2 ml graduations. The rats were
allowed to acclimate for one hour before the experiment began. After the last drug
treatment was given, water, saline, and urine levels were measured at 15 min intervals
for the first hour and then at 30 min intervals for the remaining time.
Experiment 2A. The goal of the first behavioral experiment was to examine the
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role of p44/42 MAPK activation in mediating the effects of endogenous AngII on water
and sodium intake. The animals were assigned to one of four treatments in a crossover
design, which allowed each rat to receive all treatment conditions over the course of the
study without all the animals receiving the drug combinations in the same order. The
control condition was two vehicle injections (0.9% saline, sc) with a 10-min interval
between them. All other treatments included injections of furosemide and, 10 min later,
captopril. Icv injections were given 15 minutes before the furosemide injection. Fluid
ingestion was measured for three hours when animals were given furo/cap or saline.
Based on this initial study, it was noted that the induced ingestion mainly occurred within
the first 90 minutes; therefore, subsequent studies used this time course. To assess the
role of AT1R, animals were treated with irbesartan icv, and to assess the role of p44/42
MAPK, they were injected with U0126 icv. Water and 1.5% saline intakes as well as
urine output, were measured for 90 minutes.
Experiment 2B. The goal of the second behavioral experiment was to examine
the role of p44/42 MAPK activation on water intake in the absence of sodium ingestion.
The animals were treated with either vehicle or U0126 icv followed 15 minutes later by
furosemide, and 10 minutes later by captopril in a crossover design. Rather than being
presented with two bottles, as in the first experiment, animals were presented with a
single bottle containing tap water. Water intake was monitored for the next 90 minutes.

AVP and OT Secretion
Experiment 3A. Rats were pretreated centrally with either vehicle, irbesartan, or
U0126, followed by either vehicle or furo/cap, sc as described above. Thirty minutes
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after the captopril injection rats were rapidly decapitated and trunk blood was collected
into 10 ml BD Vacutainer blood collection heparinised glass tubes on ice (Franklin
Lakes, NJ).

The thirty-minute time point was chosen based on the emergence of

diuresis and drinking behavior in our initial furo/cap studies. Additionally, the ELISA
study showed that U0126 effectively inhibited p44/42 MAPK activation at this time point.
Previous research examined a ninety-minute time point after furo/cap treatment, but did
not observe increases in oxytocin (Thunhorst et al., 1994).

The tubes then were

centrifuged at 4oC at 1300 relative centrifugal force (rcf) for 10 min.

The plasma

supernatant was extracted with acetone and petroleum ether. Plasma levels of AVP and
OT were measured with a specific radioimmunoassay performed by the laboratory of Dr.
Joseph G. Verbalis, as described previously (Verbalis, McHale, Gardiner, & Stricker,
1986). The standard curve for each peptide was linear between 0.5 and 10.0 pg per
tube with the use of a synthetic AVP and between 0.25 and 5 µU per tube with the OT
standard (Bachem Americas, Inc, Torrance, California).

The minimum detectable

concentration of AVP or OT in extracted plasma was 0.5 pg/ml and 0.25 µU/ml,
respectively. The AVP antiserum (R-4) displayed < 1% cross-reactivity with OT, and the
OT antiserum exhibited < 1% cross-reactivity with AVP.
Experiment 3B.

Rats were assigned to one of the following pretreatment

groups: vehicle or U0126 (1mM) followed 15 minutes later by AngII (20 ng) icv. Two or
fifteen minutes after the last icv injection, rats were rapidly decapitated and their trunk
blood was collected. The two- and fifteen-minute time points were based on the
emergence of drinking behavior in previous exogenous AngII studies and selected to
establish the range of neurohypophysial hormone levels in the plasma after the
treatments. Previous studies used a 90-second time point and observed increases in
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plasma vasopressin (Gohlke et al., 2002). The protocol described in Experiment 3A was
then followed to measure AVP and OT levels.

Statistical Analysis
Data are presented as the mean ± the standard error of the mean. For the
behavioral studies, comparisons were made between the treatment conditions and over
time using repeated measure analysis of variance (two-way ANOVA; time point x
treatment).

For the p44/42 MAPK ELISA and AVP/OT radioimmunoassay results,

comparisons were made between the treatment groups (one-way ANOVA).

When

warranted, planned comparison post-hoc t-tests were performed. All hypothesis tests
used a=0.05 as the criterion level of significance. Statistical analyses were conducted
using Prism 2.0 software (La Jolla, CA).

RESULTS
Furo/cap treatment activates p44/42 MAPK in the brain
In Experiment 1, rat brain punches were collected from coronal slices for several
brain regions, namely, OVLT, SFO, PVN, SON and primary somatosensory cortex as a
control brain region (depicted in Figure 2.1). As shown in Figure 2.2A, total p44/42
MAPK levels between all of the treatment groups in the OVLT/SFO were not different
(ANOVA F (5,19) = 0.5, p>0.05).

However, p44/42 MAPK phosphorylation in the

OVLT/SFO differed between treatment groups (ANOVA (F (5,19) = 5.9, p<0.01). More
specifically, furo/cap treatment increased phospho p44/42 absorbance levels compared
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to control (1.6 ± 0.0 vs 1.1 ± 0.1, p<0.001). Furo/cap treatment paired with icv AT1R
antagonist irbesartan or MEK inhibitor U0126 significantly reduced absorbance levels
compared to furo/cap with vehicle pretreatment (1.1 ± 0.1 vs 1.1 ± 0.0 vs 1.6 ± 0.0,
respectively; p<0.01).
Likewise, Figure 2.2B illustrates that total p44/42 MAPK levels were equivalent
for all treatment groups in the PVN/SON (ANOVA F (5,19) = 0.2, p>0.05). However,
p44/42 MAPK phosphorylation in the PVN/SON of the hypothalamus differed between
treatment groups (ANOVA F (5,19) = 10.4, p<0.001). In particular, furo/cap treatment
augmented phospho p44/42 absorbance levels compared to control (1.7 ± 0.1 vs 1.1 ±
0.0, p<0.001). Pretreatment with either icv irbesartan or U0126 reduced absorbance
levels of phospho p44/42 MAPK compared to furo/cap with vehicle pretreatment (1.2 ±
0.1 vs 1.0 ± 0.1 and 1.7 ± 0.1, respectively; p<0.001).
As shown in Figure 2.2C, the control brain region S1 had similar levels of p44/42
total MAPK regardless of treatment group (ANOVA (F (5,19) = 0.4, P>0.05). Unlike
OVLT/SFO and PVN/SON, S1 did not show an increase in p44/42 MAPK
phosphorylation in response to furo/cap treatment (ANOVA F (5,19) = 0.1, P>0.05).

The role of p44/42 MAPK in furo/cap-induced water and sodium ingestion
Consistent with previous work (Thunhorst et al., 1994), the furo/cap protocol
produced a rapid diuresis and prompt water and sodium ingestion (as shown in Figure
2.3). A two-way ANOVA established a strong main effect of furo/cap treatment on urine
output (F (1, 112) = 72.4, p<0.0001). Animals that received furo/cap treatment excreted
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significantly more urine during the three hours after treatment than controls (13.6 ± 1.1
versus 2.9 ± 0.5 ml, p<0.001). This increase in urine output was first significant within 15
minutes of treatment (p<0.01). These animals also drank water robustly in response to
the furo/cap treatment compared with controls (F (1,112) = 23.5, p<0.001; 7.8 ± 1.4
versus 0.8 ± 0.2 ml, p<0.001). In addition, furo/cap-treated rats consumed substantial
amounts of 1.5% NaCl solution compared with controls during this three hour time period
(F (1,112) = 9.0, p<0.01; 5.7 ± 1.5 versus 0.7 ± 0.2 ml, p<0.001). The time point at
which the furo/cap group intake became significantly elevated compared with the control
group was 45 min for water intake (p<0.01) and 60 min for sodium intake (p<0.05) after
the captopril injection.
Experiment 2A verified that furo/cap-induced water and sodium ingestion could
be attributed, at least in part, to AT1Rs. In particular, rats were pretreated centrally with
the AT1R antagonist irbesartan (200 ng/ul) 15 min before furo/cap treatment (Hines,
Fluharty, & Yee, 2003) A two-way ANOVA established a main effect of irbesartan on
furo/cap induced water intake compared to furo/cap controls (F (1,275) = 11.2, p<0.01).
A similar main effect occurred with irbesartan treatment and furo/cap-induced sodium
intake (F (1,270) = 9.2, p<0.01). As shown in Figure 2.4A, irbesartan pretreatment
decreased furo/cap-induced water intake by 50% over 90 minutes (5.8 ± 0.6 versus 2.9
± 0.5 ml, p<0.001), first becoming significant at 45 minutes (p<0.001). Sodium intake
was reduced by 56% at 90 minutes (4.6 ± 0.6 versus 2.0 ± 0.5 ml, p<0.001), first
becoming significantly attenuated at 45 minutes (p<0.01). This level of suppression of
furo/cap-induced water and sodium intake by an AT1R antagonist is consistent with
previous findings (Thunhorst et al., 1994).
Next, we investigated whether furo/cap-induced water and sodium ingestion
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could be attributed, at least in part, to p44/42 MAPK signaling. In particular, rats were
pretreated centrally with the MEK inhibitor U0126 15 min before the furo/cap treatment.
The dose of U0126 was chosen based on previous efficacy (Daniels D, Mietlicki EG,
Nowak EL, Fluharty SJ, 2009), and was validated in our Experiment 1. A two-way
ANOVA did not reveal a main effect of U0126 on furo/cap-induced water intake
compared to controls (F (1,275) = 2.5, p = 0.1). However, there was a significant
interaction between treatment and time (p<0.01). U0126 decreased furo/cap-induced
water intake by 30% at 90 minutes (5.8 ± 0.6 versus 4.1 ± 0.5 ml, p< 0.01), as shown in
Figure 2.4A. A two-way ANOVA revealed a main effect of U0126 on furo/cap-induced
sodium intake (F (1,280) = 13.0, p<0.001). U0126 reduced sodium intake by 60% (4.5
± 0.6 versus 1.8 ± 0.5 ml, p < 0.001), first becoming significant at 30 min (p<0.05). Urine
volume measurement confirmed that neither irbesartan nor U0126 pretreatment the
interfered with the diuretic effectiveness of the furo/cap treatment (12.3 ± 0.9 versus 12.4
± 1.4 versus 14.0 ml, respectively; data not shown).
Previous work that suggested that p44/42 MAPK signaling mediates AngIIinduced sodium appetite but not thirst; however, we observed a reduction in water intake
in the U0126-treated animals, albeit not until the 90-min time point. We reasoned that
this delayed suppression of water intake was an artifact of the two-bottle test, given that
consumption of hypertonic saline would provide an osmotic stimulus for water intake.
Thus, as U0126 suppresses sodium ingestion, it may indirectly effect to reduce water
intake. This interpretation of the data is supported by the fact that U0126 suppressed
sodium intake at 30 min, and subsequently reduced water intake at 90 min. To test this
hypothesis, the effect of U0126 was examined in a single-bottle test. In this case, a twoway ANOVA revealed that water intake was not significantly decreased with U0126
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treatment (F (1,105) = 1.2, p = 0.3), compared with animals only treated with furo/cap.
Furo/cap versus furo/cap + U0126 groups drank 4.3 ± 0.8 versus 5.0 ± 0.9 ml,
respectively, at the 90-minute time point (Figure 2.4B).

The role of p44/42 MAPK in furo/cap- and AngII-induced AVP and OT release
Experiment 3A investigated whether or not p44/42 MAPK signaling mediated
furo/cap-induced AVP and OT secretion. Rats were pretreated with vehicle, irbesartan,
or U1026 icv paired with either vehicle or furo/cap sc. Thirty minutes after captopril
treatment, plasma AVP levels differed between treatment groups (Figure 2.5; ANOVA (F
(5,19) = 6.2, P<0.01).

Post hoc analysis revealed that furo/cap stimulated AVP

compared to vehicle treatment (1.3 ± 0.2 vs 0.6 ± 0.1 pg/ml, p<0.05). However, when
animals were pretreated centrally with irbesartan or U0126, furo/cap-induced AVP
secretion was not significantly reduced compared with vehicle pretreatment (1.4 ± 0.1 vs
1.7 ± 0.3 vs 1.3 ± 0.2 pg/ml, p>0.05). Similarly, OT levels differed between groups thirty
minutes after captopril treatment (ANOVA (F (5,19) = 3.3, P<0.05). Post hoc evaluation
indicated that furo/cap stimulated OT compared to control (5.6 ± 1.0 vs 1.8 ± 0.5 pg/ml,
p<0.05). However, furo/cap treatment paired with irbesartan or U0126 centrally did not
reduce OT levels compared to furo/cap with vehicle pretreatment (6.0 ± 1.6 vs 4.7 ± 0.9
vs 5.6 ± 1.0 pg/ml, p>0.05).
In Experiment 3B, rats were pretreated centrally with either vehicle or U0126
followed by AngII (20 ng). Two or fifteen minutes after treatment, plasma AVP differed
between the groups (Figure 2.6; ANOVA (F (2,38) = 5.6, p<0.01). Given that there were
no significant differences between the 2 and 15 min time points within each treatment
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group, these data were combined. Post-hoc analysis indicated that AngII treatment
stimulated AVP secretion compared with vehicle treatment (2.5 ± 0.3 versus 1.5 ± 0.2
pg/ml, p<0.01). This level of AngII-induced AVP secretion is consistent with previous
findings (Reis, Saad, Camargo, Elias, & Antunes-Rodrigues, 2010). However, when
animals were pretreated with U0126, the AngII-induced AVP secretion was not
significantly different than when AngII was given alone (2.3 ± 0.2 versus 2.5 ± 0.3 pg/ml,
p = 0.7). Likewise, plasma OT levels was increased 2 and 15 min after AngII treatment
compared with vehicle (Figure 2.6; ANOVA F (2,35) = 5.3, p<0.01). Post hoc analyses
revealed that AngII treatment stimulated OT secretion compared with vehicle treatment
at levels congruous with previous findings (14.2 ± 2.8 versus 6.0 ± 1.3 pg/ml, p<0.01)
(Reis et al., 2010). However, AngII-induced OT secretion was not diminished by U0126
pretreatment (14.2 ± 2.8 versus 13.5 ± 2.4 pg/ml, p = 0.9).

DISCUSSION
The goal of our experiments was to uncover the role of p44/42 MAPK in both
behavioral and physiological actions of central AngII.

Experiment 1 demonstrated

p44/42 MAPK activation in certain brain regions after endogenous AngII production,
which was inhibited by an AT1R antagonist. Experiment 2 established that endogenous
AngII production promotes sodium appetite, but not thirst, via p44/42 MAPK activation.
Experiment 3 found that p44/42 MAPK activation does not mediate furo/cap- or AngIIinduced AVP and OT secretion, underscoring the selective role of p44/42 MAPK in
AngII-induced sodium appetite.
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While previous findings have demonstrated the part played by p44/42 MAPK in
AngII-induced sodium appetite, our studies confirm and extend these results (Daniels D,
Yee DK, Faulconbridge LF, Fluharty SJ, 2005). For example, although studies using
exogenous AngII-induced sodium appetite demonstrated the stimulation of p44/42
MAPK activation by AngII, they did not show its reduction by MEK inhibitor U0126 in
relevant brain regions (Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009; Daniels D,
Yee DK, Faulconbridge LF, Fluharty SJ, 2005). The present studies demonstrate that
furo/cap induces p44/42 MAPK activation in relevant forebrain areas, and that our doses
of central irbesartan and U0126 restore phospho p44/42 MAPK to control levels. The
furo/cap treatment produces high levels of circulating renin and angiotensin I, and
central AT1R appears to mediate a large proportion of the observed water and sodium
ingestion (Fitzsimons & Stricker, 1971; Thunhorst et al., 1994). The present results
further support the notion that AT1R-p44/42 MAPK activation is responsible for the
increase in sodium appetite observed in our experiments, and that the reduction of the
behavior by U0126 is due to decreased p44/42 MAPK activation in relevant AT1R
containing brain regions.

Moreover, our studies provided an additional control to

examine the unique role of p44/42 MAPK in sodium appetite through use of a single
water bottle test.
Nevertheless, our studies present their own limitations.

For example, AngII

levels in the brain may be unusually elevated by the peripheral blockade of angiotensin I
conversion using the furo/cap model.

However, in this protocol AngII production is

constrained by physiological availability of the prohormone (Thunhorst et al., 1994).
Another consideration is that furo/cap treatment may activate other interoceptive
systems apart from the renin-angiotensin-aldosterone system. For example, low- and
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high-pressure baroreceptors would detect the diuresis-induced loss of blood volume and
pressure, respectively, and relay this information to brainstem structures that may
promote thirst, sodium appetite, or both

(Thunhorst & Johnson, 1994).

Such

baroreceptor-mediated signals may explain the partial effect of irbesartan pretreatment
on water and sodium intake, and its ineffectiveness on AVP and OT secretion. Another
limitation of our studies is the combining of brain regions for the p44/42 MAPK ELISA.
An immunohistochemical approach would allow for better localization of activated p44/42
MAPK. However, the objectivity, reproducibility, and semi-quantitative nature of ELISAs
offer a clear advantage over the challenges of quantifying immunohistochemistry.
Lastly, the icv injections used in our studies are not as spatially discrete as parenchymal
injections. Future studies using local microinjections will be informative to pinpoint the
contribution of parallel signaling pathways in specific brain regions.
While demonstrating that AT1R-MAPK mediates sodium appetite, our studies
indicate that water intake and the secretion of AVP and OT do not require p44/42 MAPK
activation.

Circulating

AngII

accesses

AT1R

located

on

neurones

in

the

circumventricular organs, such as the SFO and the OVLT (Geerling & Loewy, 2008)
whose neurones project to the magnocellular neurones in the PVN and SON, which also
express AT1R (McKinley et al., 1998; Wei et al., 2009). Centrally administered AngII
induces c-Fos expression in the PVN and SON and increases the firing rate of AVP and
OT neurones (Renaud & Bourque, 1991; Roesch et al., 2001) resulting in plasma levels
of these hormones being elevated within minutes after AngII injection (Keil, RosellaDampman, Emmert, Chee, & Summy-Long, 1984). These hormones contribute to fluid
balance, with AVP prompting water retention and OT stimulating natriuresis (Conrad et
al., 1993; Ganong, 1977). In furo/cap-treated animals, the AT1R antagonist irbesartan
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does not reduce AVP and OT secretion, which suggests that other mechanisms, such as
baroreceptors, trigger neurohypophysial release in this circumstance. Experiment 3B
demonstrates

that

even

when

AngII

is

centrally

administered

neurohypophysial release, p44/42 MAPK activation is not required.

to

prompt

However, it is

possible that a role for AT1R and p44/42 MAPK in furo/cap-induced AVP and OT
release could be found at different time points. At present, it seems as though acute
AVP and OT secretion must rely on other signaling pathways, such as IP3-mediated
ionotropic events, or genotropic or structural changes mediated by other MAPK family
members.
The present study focused on a subset of the MAPK family, namely p44/42. The
role of other MAP kinases in the central effects of AngII remains unclear. It is possible
that p38 MAPK and/or JNK play a role in mediating the central actions of AngII not
blocked by the p44/42 MAPK inhibitor. Additionally, as shown in previous studies, it is
possible for some MAP kinases, but not others, to be involved in mediating central AngII
effects, such as AT1R upregulation (Wei et al., 2009). It would be important for future
studies to investigate the role of other MAP kinases in drinking behavior and
neurohypophysial release.
Studying the signaling molecules involved in the central actions of AngII is the
first step to understanding how central AngII exerts its physiological effects, but much
remains to be uncovered about the cellular mechanisms by which they mediate these
actions. For example, there are several plausible mechanisms by which p44/42 MAPK
may mediate sodium appetite in the brain. One possibility is that AngII-MAPK signaling
elicits sodium appetite by changing neuronal excitability in circumventricular neurones or
forebrain integration sites that project to motor generators involved in salt ingestive
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behavior (Geerling & Loewy, 2008; Schrader et al., 2006). This rapid effect on synaptic
transmission could explain the relatively fast time course of furo/cap-induced sodium
appetite (Numakawa et al., 2002). Alternatively, p44/42 MAPK may be involved in longterm gene transcription and protein synthesis for sodium and potassium channel
subunits or AT1R. For example, MAPK up-regulates AT1R in the SFO and PVN, and
increased levels of AngII binding to its receptor may explain the robust sodium appetite,
although not the lack of p44/42 MAPK-mediated water ingestion (Wei et al., 2009).
Other downstream consequences of p44/42 MAPK activation include rearrangements of
the cytoskeleton, which could include structural neural plasticity

(Olsen, Reszka, &

Abraham, 1998; Schenk et al., 2005). This mechanism is highlighted in a study by
Swank and Sweatt, which found that p44/42 MAPK activation is important for plasticity in
taste learning (Swank & Sweatt, 2001). Other research has demonstrated that sodium
appetite is associated with dendritic growth and the development of dendritic spines in
the nucleus accumbens (Roitman, Na, Anderson, Jones, & Bernstein, 2002). p44/42
MAPK activation may underlie strengthened connections within this brain region
associated with incentive sensitization, which would explain the sudden avidity for
sodium.

It will be imperative for future studies to discern what downstream

consequences of p44/42 MAPK signaling contribute to AngII-induced sodium appetite,
keeping in mind there may be several parallel mechanisms.
Extending beyond drinking behaviors and neurohypophysial secretion, central
AngII has a multitude of actions in the brain. For example, AngII causes sympathetic
stimulation, hypothalamic-pituitary-adrenal activation, increased sympathetic tone, and
ultimately an increase in mean arterial pressure (Peach, 1977). Other investigators have
begun to uncover the AT1R signaling mediating these actions. Specifically, Wei et al
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have shown that p44/42 MAPK mediates the effect of central AngII to increase
sympathetic nerve activity in heart failure, another syndrome adversely affected by salt
intake

(Wei, Yu, Zhang, Weiss, & Felder, 2008). An important avenue for future

investigation is to determine the locus within the network of AngII-modulated neural
circuitry wherein sodium appetite and sympathetic activity share a common dependence
on p44/42 MAPK activation. Another key question to address is the effect of elevated
p44/42 MAPK activity in specific brain regions on the many central actions of AngII.
In summary, these studies provide new evidence that the diverse effects of
central AngII rely on divergent signaling mechanisms. More specifically, we found that
sodium appetite requires p44/42 MAPK activation, whereas thirst and neurohypophysial
hormone secretion do not. It will be important for future studies to assess the role of
both p44/42 MAPK and other MAPK kinases in other central AT1R actions that remain
undefined, such as hypothalamic-pituitary-adrenal activation. Moreover, it will be critical
to find the downstream targets of MAPK and determine the cellular mechanism of AngII
in exerting these central effects.

PERSPECTIVES
Elements of the renin-angiotensin-aldosterone system are frequently implicated
in the pathogenesis of hypertension, although the cause of hypertension is often
unknown (Marc & Llorens-Cortes, 2011). Hypertension is a common and serious health
concern (Karppanen & Mervaala, 2006). One in three adults have chronically elevated
blood pressure, which shortens a person’s life span by three to five years (Del Giudice,
Pompa, & Aucella, 2010).
	
  

The identification of signaling-selective subsets of AngII
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action in the brain presents an opportunity to more precisely target central pathways that
regulate blood pressure (Felder, Yu, Zhang, & Wei, 2009; Margolius & Bodenheimer,
2010)
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Figure 2.1. Examining Furo/Cap-MAPK
activation in the brain.
Drawing of a coronal hemi section of rat
brain depicting the brain regions of interest
for p44/42 MAPK activation assays. Circles
within each brain region represent 1 mm
micropunches collected for the p44/42
MAPK ELISAs. The brain regions examined
include circumventricular organs OVLT and
SFO, as well as the PVN and SON of the
hypothalamus. Additionally, the S1 was
collected as a control brain region to assay
P44/42 MAPK activation. Abbreviations: S1
= primary somatosensory cortex, CPu =
caudate putamen, MS = medial septal
nucleus, OVLT = organum vasculosum of
the lateral terminalis, SFO = subfornical
organ, fi = fimbria of the hippocampus, ic =
internal capsule, PVN = paraventricular
nucleus of the hypothalamus, SON =
supraoptic nucleus of the hypothalamus.
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Figure 2.2. Furo/Cap activates MAPK in key brain areas; this is reduced by an AT1R and
MEK inhibitor.
Bar graphs illustrating the levels of total p44/42 MAPK and phospho p44/42 MAPK in the
OVLT/SFO (panel A), PVN/SON (panel B), and S1 (panel C) after either vehicle or furo/cap
treatment sc and either vehicle, irbesartan, or U0126 administered icv (n = 3-5/group). Total
p44/42 MAPK levels do not change, whereas furo/cap treatment increases phosphorylated
p44/42 MAPK in the OVLT/SFO and PVN/SON, but not in S1. Both irbesartan and U0126 prevent
this furo/cap induced increase in p44/42 MAPK phosphorylation. Abbreviations: OVLT = organum
vasculosum of the lateral terminalis, SFO = subfornical organ, PVN = paraventricular nucleus of
the hypothalamus, SON = supraoptic nucleus of the hypothalamus, S1 = primary somatosensory
cortex.
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Figure 2.3. Furo/Cap increases urine output as well as water and sodium intake.
Line graphs illustrating the effect of furo/cap treatment on urine volume (panel A) and water and
sodium intake during a two-bottle test (panel B). On the x axis, zero minutes represents the time
of captopril injection. Compared with vehicle treatment, rats given furo/cap treatment excreted
significantly more urine within 15 minutes (n=16). Furo/Cap also induced a robust intake of water
and 1.5% sodium within 45 minutes and 60 minutes of treatment, respectively. Asterisks indicate
that p<0.01 when comparing Furo/Cap to vehicle treatment.
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Figure 2.4. Furo/Cap sodium intake but not water intake is mediated by MAPK.
Line graphs illustrating the effect of blocking AT1R receptors and MAPK activation after furo/cap
treatment in a two bottle test (panel A) and in a one bottle test (panel B). On the x axis, zero
minutes represents the time of captopril injection. In the two bottle test, compared with Furo/Cap
+ Vehicle treatment, rats given the Furo/Cap + AT1R antagonist irbesartan treatment consumed
significantly less water within 45 minutes after treatment (n=28). Irbesartan also reduced the
intake of 1.5% saline within 45 minutes of treatment. Compared with Furo/Cap + vehicle
treatment, rats given Furo/Cap + the MEK inhibitor U0126 treatment consumed significantly less
water within 90 minutes after treatment and significantly less saline within 30 minutes of treatment
(n=28). In the one bottle test, compared with vehicle treated, rats given the MEK inhibitor U0126
treatment consumed similar amounts of water (n=12). Asterisks indicate that p<0.05 when
comparing to Furo/Cap + Veh treatment. Stats for Furo/Cap + Veh compared to Veh are shown in
Figure 2.3.
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Figure 2.5. Furo/Cap-induced
Vasopressin and Oxytocin release is
not mediated by MAPK.
Bar graphs illustrating the role of p44/42
MAPK activation on Furo/Cap-induced
neurohypophysial secretion. Plasma AVP
(Panel A) and OT (Panel B) after vehicle
or Furo/Cap treatment combined with
either vehicle, irbesartan, or U0126
administered
icv
(n=
3-5/group).
Furo/Cap-induced AVP and OT secretion
was not diminished with either the AT1R
antagonist irbesartan or the MEK inhibitor
U0126. Abbreviations: AVP = arginine
vasopressin, OT = oxytocin.

	
  

Fig 2.6. AngII-induced Vasopressin and Oxytocin
Release is not mediated by MAPK.
Bar graphs illustrating the effect of inhibiting p44/42
MAPK activation on AngII-induced neurohypophysial
hormone secretion. Plasma AVP (Panel A) and OT
(Panel B) levels two and fifteen minutes after icv Veh,
AngII, or U0126 plus AngII (n = 10-16/group). AngIIinduced AVP and OT levels were not inhibited with
the MEK inhibitor U0126. Abbreviations: AVP =
arginine vasopressin, OT = oxytocin.
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CHAPTER 3: THE ROLE OF THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS
AND THE ORGANUM VASCULOSUM LATERAL TERMINALIS IN THE CONTROL OF
SODIUM APPETITE IN MALE RATS

Laura A. Grafe1, Annie Takacs2, Daniel K. Yee3, and Loretta M. Flanagan-Cato1,2,4
Neuroscience Graduate Group1, Departments of Psychology2 and Animal Biology3
and the Mahoney Institute of Neurological Sciences4, University of Pennsylvania,
Philadelphia Pennsylvania, USA 19104

Abbreviated title: Hypothalamic control of sodium appetite

Key words: Aldosterone; Angiotensin; Oxytocin; Receptor Signaling; Sodium Appetite
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SUMMARY
Angiotensin II (AngII) and aldosterone cooperate centrally to produce a robust
sodium appetite. The intracellular signaling and circuitry that underlie this interaction
remain unspecified. Male rats pretreated with deoxycorticosterone (DOC; a synthetic
precursor of aldosterone) followed by central injections of AngII exhibited a marked
sodium intake, as classically described.

Disruption of inositol trisphosphate (IP3)

signaling, but not extracellular-regulated receptor kinase 1 and 2 (ERK1/2) signaling,
prevented the cooperativity of DOC and AngII on sodium intake.

The pattern of

expression of the immediate early gene product cFos was used to identify key brain
regions that may underlie this behavior. DOC pretreatment augmented AngII-induced
cFos expression in the organum vasculosum lateral terminalis (OVLT) and conversely
dampened cFos induction in the paraventricular nuclei (PVN) of the hypothalamus.
Finally, to explore the possible link between activity in the PVN and the OVLT, action
potentials in the PVN were inhibited with intraparenchymal lidocaine injections.

As

predicted, this treatment blocked AngII-induced cFos expression in the PVN and
exaggerated AngII-induced sodium ingestion. Intriguingly, this treatment also increased
the number of neurons in the OVLT expressing cFos. Collectively, these results suggest
that the behavioral cooperativity between DOC and AngII involves the alleviation of an
inhibitory signal relayed from the PVN to the OVLT.
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INTRODUCTION
	
  
The hormones angiotensin (AngII) and aldosterone are key defenders of
electrolyte balance, blood volume, and blood pressure (Peach, 1977). In the event of
sodium depletion, hypovolemia, and/or hypotension, AngII and aldosterone are
produced, which engage homeostatic responses, including a prodigious drive for sodium
consumption

(Ganong, 1977).

Steady progress has been made in revealing the

independent natriorexic effects of AngII and aldosterone; however, the mechanism for
the cooperative actions of AngII and aldosterone to promote a greater than additive
effect on sodium ingestion remains unclear.
Humoral AngII and aldosterone appear to have separate initial targets in the
brain. Circulating AngII binds to Angiotensin Type 1 Receptors (AT1R) in the subfornical
organ (SFO) and organum vasculosum lateral terminalis (OVLT), brain regions with an
incomplete blood-brain barrier (Ganong, 1984). The SFO and OVLT relay information to
the paraventricular nucleus (PVN) and supraoptic nucleus (SON) (McKinley et al., 1992;
Miselis, 1981) to prompt secretion of arginine vasopressin (AVP) and oxytocin (Bisset et
al., 1971). The downstream network involved in ingestive behavior remains unspecified.
The AT1R, as a G protein coupled receptor, associates with Gq to trigger inositol 1,4,5triphosphate (IP3) production and Ca2+ mobilization (Beresford MJ, 1992; Enjalbert et
al., 1986; Smith et al., 1984; Taylor, Smith, & Exton, 1990).

In parallel, mitogen-

activated protein kinase kinase (MEK) becomes phosphorylated, which activates the p42
and p44 isoforms of mitogen-activated protein kinase, also referred to as extracellular
signal-regulated kinase 1 and 2 (ERK1/2) (Sadoshima et al., 1995). ERK1/2 is activated
in the SFO and PVN after a central AngII injection (Wei et al., 2009). Furthermore,
whereas the IP3 signaling mediates AngII-induced thirst, the ERK1/2 signaling pathway
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mediates sodium appetite (Daniels et al., 2005; Daniels, Mietlicki, Nowak, & Fluharty,
2009; Felgendreger, Fluharty, Yee, & Flanagan-Cato, 2013).

Aldosterone-specific

actions rely on the enzyme hydroxysteroid dehydrogenase 2 (HSD2), which oxidizes
glucocorticoids into an inactive metabolite (Funder, Pearce, Smith, & Smith, 1988). MR
and HSD2 are co-localized in the nucleus of the solitary tract (NTS), which receives
gustatory projections, possibly modulating the taste of sodium (Geerling et al., 2006).
Given that the actions of AngII and aldosterone have different primary sites of action in
the brain, determining the site of convergence may help to explain their behavioral
cooperativity.
It has been proposed that the natriorexic effect of Aldo and AngII on sodium
ingestion may be based on disinhibition

(Blackburn, Demko, Hoffman, Stricker, &

Verbalis, 1992; Stricker & Verbalis, 1987). Of particular relevance, mineralocorticoid
treatment reduces AngII-induced activation of the OT neurons in the PVN and SON
(Roesch et al., 2001; Stricker & Verbalis, 1996; Stricker & Verbalis, 2004), although, the
exact role of oxytocin in the natriorexic effect of AngII is not clear (Blackburn et al.,
1992; Fitts et al., 2003; Rigatto, Puryear, Bernatova, & Morris, 2003). To investigate the
neural integration that underlies the Aldo and AngII potentiation of sodium appetite, we
took a multidisciplinary approach using behavioral pharmacology, measures of signal
transduction, reversible lesions, and functional neuroanatomy. The results implicate a
novel inhibitory link from the PVN to the OVLT, inhibited by mineralocorticoids,
comprising a disinhibitory control of sodium ingestion.
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MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats (n = 68) that weighed between 225-250 g were
obtained from Charles River Laboratories (Wilmington, MA, USA). Rats were housed in
groups of two in plastic tubs with standard bedding and with food and water available ad
libitum, except during experimental procedures. The temperature in the colony was
maintained at 22 °C with a 12:12 h reversed light/dark cycle. Animals were allowed at
least one week to acclimate to the colony before any procedures were performed. The
Institutional Animal Care and Use Committee of the University of Pennsylvania approved
all procedures with animals.

Drugs
Deoxycorticosterone Acetate (DOC; Sigma, St Louis, MO) was administered
subcutaneously (sc) at a dose of 0.25 mg in 0.2 mL of sesame oil (Sigma, St Louis, MO).
DOC is typically used instead of aldosterone because it penetrates the blood brain
barrier more easily than Aldo due to its low capacity for hydrogen bond formation
(Geerling & Loewy, 2009). Sesame oil was administered at .2mL sc as a control. The
specific doses for each drug given icv were as follows: 2.0 or 20.0 ng AngII in a volume
of 2.0 ul (Bachem, King of Prussia, PA), 2.0 nmol U0126 dissolved in 10% DMSO in a
volume of 2.0 ul (Promega, Madison, WI), 20.0 ng Xestospongin-C (XC) dissolved in 2%
DMSO in a volume of 2.0 ul (Tocris Bioscience, Minneapolis, MN), 8.5 nmol/side of 2%
lidocaine in a volume of .4 ul (Phoenix Pharmaceuticals, Burlingame, CA), 10.0 µg
oxytocin in a volume of 1 µL (Bachem, King of Prussia, PA). Artificial cerebrospinal fluid
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(aCSF; R&D Systems, Minneapolis, MN) plus 10% DMSO was administered icv as a
vehicle control in a volume of 2.0 ul.

Surgeries
Surgeries were performed in aseptic conditions. Animals were anesthetized with
isofluorane gas before being fixed in a stereotaxic frame and implanted with a 26-gauge
guide cannulae (Plastics One, Roanoke, VA, USA) aimed at the lateral ventricle. For the
lateral ventricle surgeries, coordinates were: 0.48 mm caudal to bregma, 1.6 mm from
mid-line and 4.2 mm ventral to dura mater. For the lidocaine experiments, an additional
26-gauge double guide cannula (0.8 mm apart) was implanted into the PVN. For PVN
double cannulae, coordinates were: 1.8mm caudal to bregma, 0.4 mm from the mid-line
and 7.7 mm ventral to dura mater. These coordinates were chosen to allow an internal
injection cannula to extend beyond the guide cannula into either the ventricular space or
the PVN itself. The cannulae were fixed in place with dental cement and bone screws,
and the animals were allowed at least five days to recover before verification procedures
were performed. After surgery, animals were injected with yohimbine (0.11 mg/kg, Ben
Venue Laboratories Bedford, OH). Upon awakening, animals were singly housed.
Five days after surgery and prior to undergoing experimental treatments, animals
were tested for correct lateral ventricle cannula placement and patency. They were
given an icv injection of 20.0 ng of AngII diluted in aCSF via a Hamilton syringe
connected with PE-10 tubing to an injector that terminated 1 mm beyond the guide
cannula. Animals were excluded from the experiment if they failed to demonstrate a
drinking response in less than 30 seconds, consuming at least 3 ml of water, in two
separate AngII challenges. Animals began behavioral testing three days after the icv
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test injections.

Behavioral Studies
Rats were placed in individual wire mesh-bottomed cages with water and food
available ad libitum. One day prior to injections, rats acclimated for one hour to two 25ml bottles containing tap water and 1.5% saline, each marked with 0.2 ml graduations.
Vehicle or DOC (0.25 mg) was administered to each rat in 0.2 mL of sesame oil twice
daily (ten hours apart) for three days.
To investigate the role of ERK1/2 in this model of water and sodium
consumption, rats were assigned to specific icv conditions on the fourth day: Vehicle,
U0126, AngII, or U0126 plus AngII. U0126 was administered 15 min before AngII in the
last condition (Daniels et al., 2009; Felgendreger et al., 2013). To examine the role of
the OVLT activation in the potentiation of sodium appetite, rats were assigned to specific
icv conditions on the fourth day: Vehicle, XC, AngII, or XC plus AngII. XC was
administered 20 min before AngII in the last condition (Brennan et al., 2008; Li, Ji, &
Neugebauer, 2011). To evaluate the role of the PVN in DOC and AngII-induced sodium
appetite, rats were administered either veh or lidocaine directly into the PVN over one
min, followed 5 min later by injection of vehicle or AngII icv (Fernandes, Tavares, Pelosi,
& Correa, 2007; Flanagan, Dohanics, Verbalis, & Stricker, 1992). The bilateral lidocaine
injection was performed using a dual infusion pump (Harvard Apparatus, Holliston, MA).
In an additional study examining the role of oxytocin in sodium appetite, oxytocin or
vehicle was administered icv 15 min prior to injections of lidocaine and AngII
(Blackburn, Stricker, & Verbalis, 1992).
	
  

	
  
53	
  

For all behavioral experiments, after the last drug treatment was given, rats were
returned to their cages, and water and saline levels were measured at 15 min intervals
for the first hour and then at 30 min intervals for the next hour. Food was not available
during behavioral testing.

Western Blot
Animals were pre-treated twice daily for three days (ten hours apart) with
vehicle or DOC, as described above. On day four, rats were administered either vehicle,
2 ng AngII, or 20 ng AngII icv. Two minutes after the last injections, animals were rapidly
decapitated and brains were flash frozen in hexane over dry ice. Using a cryostat, 1 mm
punches of brain regions of interest (OVLT, SFO, PVN, SON) were collected from 300
µm slices. The OVLT and SFO were combined and the PVN and SON punches were
combined from each rat to ensure sufficient tissue. Punches were immersed in lysis
buffer containing 25 mM Tris-HCl (pH 8), protease inhibitors (pepstatin, leupeptin,
aprotinin), and phosphatase inhibitors (sodium pyrophosphate, sodium fluoride, sodium
molybdate, phenylarsin oxide, and sodium orthovanadate).

The OVLT/SFO and

PVN/SON punches were immersed in 50 and 100 uL of lysis buffer, respectively. Brain
punches were sonicated for 3 seconds followed by centrifugation at 14,000 rpm in 4°C
for 15 minutes. Supernatant was collected and a Bicinchoninic acid (BCA) protein assay
was performed on five microliters of each sample. Based on the protein levels detected
by BCA, appropriate amounts of sample and sample buffer were loaded into wells of a
sodium dodecyl sulfate polyacrylamide gel. Western blot for phospho- and total ERK1/2
was performed using the LiCor Odyssey System. The following antibodies were used:
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phospho-ERK1/2 (Thr202/Tyr204) (E10) Mouse mAb #9106 (Cell Signaling, Danvers,
MA); Erk 1 Antibody (C-16): sc-93 (Santa Cruz Biotechnology, Inc, Santa Cruz, CA);
IRDye 800CW Goat anti-Mouse IgG (H + L) (Li-Cor Biosciences, Lincoln, NE); IRDye
680LT Goat anti-Rabbit IgG (H + L) (Li-Cor Biosciences, Lincoln, NE).

cFos immunohistochemistry
To observe brain activation after DOC and AngII treatments, rats were pretreated twice daily for three days (ten hours apart) with vehicle or DOC. On day 4, rats
were administered either vehicle or 20 ng AngII icv. To determine the efficacy of XC in
blocking calcium release, rats were injected icv with either vehicle, XC, AngII, or XC plus
AngII. To examine the effect PVN inactivation on cFos expression in other brain areas,
rats were injected with either: lidocaine or vehicle in the PVN, followed 5 min later by
either: vehicle or 20 ng AngII icv. Sixty minutes after the last icv injection in each study,
each rat was anesthetized with 50 mg/kg ketamine and 20 mg/kg xylazine,
intraperitoneally (ip). They were perfused transcardially with 100 mL of heparinized
saline followed by 200 mL 4% paraformaldehyde (Electron Microscopy Sciences, Fort
Washington, PA). The brains were isolated, post-fixed in paraformaldehyde overnight at
4°C, then submerged in 20% sucrose in .1M phosphate buffer for three days. Coronal
sections were cut on a freezing microtome into three serial sets of 40-um-thick sections.
These slices encompassed the organum vasculosum of the lateral terminalis (OVLT),
subfornical organ (SFO), paraventricular nucleus of the hypothalamus (PVN), and the
supraoptic nucleus of the hypothalamus (SON). One set from each animal underwent
immunohistochemical staining and analysis.

	
  

	
  
55	
  

Sections were washed in Tris-buffered saline (TBS; pH 7.4) then incubated with
a cFos antibody (1:500, sc-52, rabbit; Santa Cruz Biotechnology, Santa Cruz, CA) in
TBS with .2% TritonX-100 and 3% normal donkey serum (Jackson Immunoresearch;
West Grove, PA) overnight at 4°C. After several washes, sections were incubated with a
Biotin-SP-conjugated

AffiniPure

Donkey

Anti-rabbit

IgG

(1:100,

Jackson

Immunoresearch) in TBS with .2% TritonX-100 and 3% normal donkey serum for 2
hours at room temperature. After several washes, sections were incubated with the
Vectastain ABC kit (Vector Laboratories, Burlingame, CA) for one hour.

This was

followed by another set of washes before staining with 3’3’-diaminobenzidine (SigmaAldrich, St Louis, MO) for 10 minutes.

After a final set of washes, sections were

mounted on slides, air-dried, and cover slipped with DPX mounting media (Electron
Microscopy Sciences: Fort Washington, PA).
Images were acquired with a digital camera (Diagnostic Instruments, Sterling
Heights, MI, model RTKE), maintaining the same microscope and camera settings to
ensure the same level of light and exposure for all images. Background was subtracted
from images using Photoshop, and images were thresholded to the same level (200).
Images were further analyzed in NIH Image J using standardized boxes for each brain
region (calculated using Paxinos & Watson Rat Brain Atlas), using the analyze particles
function. Pixel size minimum was 15 and circularity was set to 0.35.

Oxytocin Secretion
Animals were pre-treated twice daily for three days (ten hours apart) with vehicle
or DOC, as described previously. On day four, rats were administered either vehicle or
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20 ng AngII icv. Two minutes after the last injections, animals were rapidly decapitated
and trunk blood was collected into 10 ml BD Vacutainer blood collection heparinized
glass tubes on ice (Franklin Lakes, NJ).

The tubes then were centrifuged at 4oC at

1300 relative centrifugal force for 10 min. The plasma supernatant was extracted with
acetone and petroleum ether. Plasma levels of oxytocin and AVP were measured with a
specific radioimmunoassay performed by the laboratory of Dr. Joseph G. Verbalis, as
described previously (Verbalis et al., 1986). The standard curve for each peptide was
linear between 0.25 and 5 µU per tube with the oxytocin standard and between 0.5 and
10.0 pg per tube with the use of a synthetic AVP (Bachem Americas, Inc, Torrance,
California).

The minimum detectable concentration of oxytocin or AVP in extracted

plasma was 0.25 µU/ml and 0.5 pg/ml, respectively. The oxytocin antiserum exhibited <
1% cross-reactivity with AVP, and the AVP antiserum (R-4) displayed <1% crossreactivity with oxytocin.

Statistical Analysis
Data are presented as the mean ± the standard error of the mean.

For all

experiments, comparisons were made between treatment groups (with either a one-way,
two-way, or three-way ANOVA). When warranted, planned comparison post-hoc t-tests
were performed. All hypothesis tests used α=0.05 as the criterion level of significance.
Statistical analyses were conducted using Prism 2.0 software (La Jolla, CA) for one-way
or two-way ANOVAs and Statistica 12 Ultimate Academic Bundle (Tulsa, OK) for threeway ANOVAs.
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RESULTS
The Role of ERK1/2 in DOC and AngII-induced Sodium Appetite
Consistent with previous research (Fluharty & Epstein, 1983), DOC pretreatment
potentiated AngII-induced sodium intake, but not water intake (Figure 3.1A). A two-way
ANOVA established a main effect for both AngII (F(2,54) = 10.7, p<0.001) and DOC
(F(1,54) = 29.6, p<0.001) on sodium intake, as well as an interaction between the two
treatments (F(2,54) = 3.2, p = 0.046; n = 12 rats/treatment group). Bonferonni post-hoc t
tests revealed a significant difference between each dose of AngII and the respective
DOC pre-treated condition (p<0.001 for the 2 ng AngII dose; p = 0.020 for the 20 ng
AngII dose). Regarding water intake, a two-way ANOVA supported a main effect for
AngII (F(2, 60) = 31.1, p<0.001), but not DOC (F(1,60 = 0.7, p = 0.400), to increase
water intake.
The role of ERK1/2 in the interaction between AngII and DOC was investigated
by using the MEK inhibitor U0126 (Figure 3.1B). U0126 significantly reduced sodium
intake induced by 20 ng AngII alone (6.6±1.8 versus 2.2±1.0 ml, p = 0.003; planned
comparison t tests; n = 18 rats/treatment group), as shown previously (Daniels et al.,
2009; Felgendreger et al., 2013). However, the MEK inhibitor U0126 did not reduce
sodium intake elicited by combined DOC and AngII treatments; in the 2ng AngII
condition, U0126 enhanced DOC/AngII induced sodium appetite (5.1±0.9 versus 8.5±0.8
ml, p = 0.010, for the 2.0 ng dose of AngII; 11.3±1.4 versus 12.6±2.3 ml, p = 0.270, for
the 20 ng dose of AngII).

U0126 did not diminish the effect of AngII on water

consumption.
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The effect of these hormonal treatments on the activation of ERK1/2 in OVLT,
SFO, PVN, and SON then was measured by Western blot analysis, as shown in Figure
3.1C. A two-way ANOVA supported a main effect of AngII alone, but not DOC alone, on
ERK1/2 phosphorylation (F(2,20)=4.1, p = 0.030; n = 6 rats/treatment group) for both
OVLT/SFO and PVN/SON. Post-hoc tests revealed that both doses of AngII significantly
increased phosopho-ERK1/2 compared with vehicle treatment (OVLT/SFO: 0.5±0.0 and
0.5±0.0 versus 0.3±0.0, p = 0.049 and 0.043); PVN/SON: 0.5±0.0 and 0.4±0.0 versus
0.3±0.0, p = 0.025 and 0.048). Additionally, there was a significant interaction between
DOC and AngII treatments for these brain regions (OVLT/SFO: (F(2,20) = 4.1, p =
0.031); PVN/SON: (F(2,20) = 3.9. p = 0.035)), such that in the presence of DOC, AngII
treatment no longer activated ERK1/2.

In short, these results did not support the

hypothesis that DOC potentiated the effects of central AngII on sodium appetite by
further increasing phospho-ERK1/2 levels in relevant brain regions. Nevertheless, the
negative interaction between DOC and AngII on ERK1/2 activation in circumventricular
and neuroendocrine regions suggested that further investigation of these areas was
warranted.

The interaction of DOC and AngII on cFos activation in the brain
To further explore the neurological mechanisms that underlie the behavioral
cooperativity of DOC and AngII, cFos immunohistochemistry was used to detect a
unique pattern of brain activity that might correspond to the behavioral effects of these
hormones. As illustrated in Figure 3.2A, brain sections from OVLT, SFO, PVN, and
SON were analyzed for cFos immunolabeling.
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In the OVLT, cFos levels were

significantly enhanced compared to vehicle for all treatment groups (Vehicle: 8.7±1.7,
DOC: 34.5±6.5, AngII: 29.0, DOC and AngII: 50.4; p = 0.010, p = 0.004, p = 0.020; n = 6
rats/treatment group, 4-6 sections per brain area). In the SFO, cFos levels were similar
for vehicle and DOC, but both AngII and DOC/AngII treatments significantly enhanced
staining (Vehicle: 11.5±2.6, DOC: 22.1±6.0, AngII: 56.8±5.9, DOC and AngII: 47.4±7.6; p
= 0.200, p = 0.001, p = 0.004). AngII significantly increased cFos staining compared to
vehicle in the PVN (126.3±5.3 versus 59.4±6.9, p<0.001), and DOC reduced AngIIinduced cFos staining to vehicle levels (126.3±5.3 versus 72.5±14.4, p = 0.006). In the
SON, AngII induced a significant amount of cFos staining compared to vehicle (40.4±6.6
versus 14.6±3.7, p = 0.020). There was a trend for DOC to reduce AngII-induced Fos
staining compared to AngII alone (25.4±5.0 versus 40.4±6.6, p = 0.100). In short, the
most striking interactions between DOC and AngII on cFos labeling were the enhanced
cFos staining in the OVLT and the suppressed cFos levels in the PVN.
The observation that DOC diminished the AngII-induced Fos activation in the
PVN is reminiscent of previous studies that demonstrated the DOC inhibits oxytocin
neuron activity in the PVN, thereby disinhibiting sodium intake (Roesch et al., 2001).
We tested whether the DOC treatment was associated with alterations in AngII-induced
neurohypophysial secretion. Plasma levels of oxytocin and AVP were measured by
radioimmunoassay after DOC, AngII, or both hormone treatments (Figure 3.2B). A twoway ANOVA revealed a main effect for both AngII and DOC, as well as an interaction
between the two hormones on oxytocin secretion (F(1,27) = 4.2, p = 0.049; F(1,27) =
4.4, p = 0.045; F(1,27) = 5.7, p = 0.020, n = 8 rats/treatment group). AngII increased
oxytocin levels significantly compared to vehicle (12.8±2.9 versus 6.4±0.8 pg/ml, p =
0.048). DOC reduced these AngII-induced oxytocin levels back down to control levels
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(12.8±2.9 versus 5.1±1.2 pg/ml, p = 0.035). In contrast, there was no effect of DOC on
AngII-induced AVP secretion.
Taken together, these results demonstrate a correlation between cFos
expression in the OVLT and a suppression of PVN oxytocin activity with the natriorexic
effect of combined DOC and AngII. We next sought to determine whether disruption of
cFos induction in the OVLT with an IP3 receptor antagonist would impair the behavioral
cooperativity of DOC and AngII.

The Role of IP3 in DOC and AngII-induced Sodium Appetite
IP3 signaling was blocked with an antagonist to the IP3 receptor, namely
xestospongin-C (XC). First the bioactivity of centrally administered XC was verified by
assaying AngII-induced cFos immunohistochemistry in Figure 3.3A. Given that cFos is
an immediate early gene activated by IP3-induced intracellular calcium signaling, an
effective IP3 receptor antagonist should prevent calcium signaling, and thereby cFos
expression (Clark, Balla, Jones, & Catt, 1992; Daniels et al., 2005; Jomphe, Levesque,
& Trudeau, 2003; Templeton, Wang, & Miralem, 1998; W. Zhang et al., 2012). A twoway ANOVA indicated main effects of AngII and XC, and an interaction on cFos
expression (F(1,16) = 4.7, p = 0.045; F(1,16) = 6.3, p = 0.020, F(1,16) = 6.8, p = 0.018,
respectively) in the OVLT (n= 6 rats/treatment group, 4-6 sections per brain area). In
particular, Bonferroni post-hoc tests suggest that XC pretreatment significantly reduced
the number of AngII-induced cFos-labeled neurons (9.4±2.5 versus 29.6±4.1, p = 0.002).
Labeling in the SFO exhibited a main effect for AngII, but not XC (F(1,15) = 7.2, p =
0.020; F(1,15) = 0.9, p = 0.360). However, there was a significant interaction between
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AngII and XC (F(1,15) = 5.3, p = 0.040).

Specifically, Bonferonni post-hoc tests

designated a significant reduction in cFos expression between AngII and XC plus AngII
(30.0± 4.3 versus 15.1±4.3, p = 0.035).
Having demonstrated that the XC treatment effectively blocked IP3-induced cFos
in relevant brain regions, the role of IP3 in AngII and DOC induced sodium appetite was
investigated (shown in Figure 3.3B). A three-way ANOVA indicated that sodium intake
differed between treatment groups (F(1,68) = 6.5, p = 0.010; n = 10 rats/treatment
group). Consistent with Figure 3.1, DOC enhanced AngII-induced sodium intake (p =
0.006). XC did not affect sodium ingestion in animals treated with AngII alone (8.3±1.8
versus 8.3±1.7 ml, p = 0.990). However, XC reduced the DOC and AngII enhancement
of sodium intake to levels similar to the AngII alone group (15.1±1.3 versus 10.9±1.3 ml,
p = 0.030). Likewise, a three-way ANOVA revealed that water intake differed between
treatment groups (F(1,51) = 5.8, p = 0.020). Post-hoc tests indicated that XC reduced
AngII-induced water intake (11.0±1.6 versus 6.9±1.0 ml, p = .030). However, when both
DOC and AngII were present, XC did not reduce water intake (8.7±1.1 versus 9.2±1.8
ml, p = 0.810). Taken together, these results suggests that IP3 signaling, possibly in the
OVLT, is necessary for in the cooperative actions of DOCA and AngII on sodium
appetite. Previous work suggested that DOC enhances AngII-induced sodium appetite
via the suppression of oxytocin activity in the PVN (Blackburn et al., 1992; Stricker &
Verbalis, 1987), and several findings reported here are consistent with that hypothesis.
Therefore, the next experiment was designed to manipulate PVN activity and measure
the effect on sodium appetite and neuronal activation in the OVLT.
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Sodium appetite and OVLT activation after suppression of PVN activity
Neural activity in the PVN was suppressed with bilateral injections of lidocaine
above the PVN. Behavioral analysis included only animals with cannula tract locations
verified to be above the PVN (depicted in Figure 3.4A). Animals were treated with
either vehicle or lidocaine into the PVN, followed by either vehicle or 20 ng AngII (icv). A
two-way ANOVA revealed a main effect for AngII and lidocaine, as well as an interaction
on sodium intake (F(1,20) = 21.5, p = 0.001; F(1,20) = 5.2, p = 0.035; F(1,20) = 6.7, p =
0.020; n = 10 rats/treatment group). As shown in Figure 3.4B, AngII increased sodium
intake compared to vehicle (5.6±1.0 versus 2.0±0.6 ml, p = 0.040).

Additionally,

lidocaine enhanced AngII-induced sodium intake significantly (9.5±1.2 versus 5.5±1.4 ml
p = 0.045). Conversely, a two-way ANOVA revealed a main effect for AngII but not
lidocaine on water intake (F(1,23) = 28.8, p<0.0001; F(1,23) = 0.1, p = 0.740). Post-hoc
tests denoted AngII plus or minus lidocaine treated rats drank very similar amounts of
water (9.1±1.5 versus 8.6±1.0 ml, p = 0.760), but both groups drank significantly more
than vehicle treated rats (0.5±0.5 ml, p = .02 and p = 0.009). A subset of rats was
treated with oxytocin (10.0 µg, icv) in the lidocaine plus AngII condition. Oxytocin coadministration decreased sodium intake to vehicle levels (9.5±1.2 versus 2.1±0.7 ml, p =
0.001).

However, oxytocin treatment also partially decreased water intake in the

lidocaine plus AngII group (8.6±1.0 versus 4.7±1.2 ml, p = 0.030). In summary, lidocaine
in the PVN enhanced AngII-induced sodium intake, but not water intake, mimicking the
effects of DOC pretreatment.
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After the behavioral studies, AngII-induced cFos immunohistochemistry was
performed on the brains of these animals to verify the efficacy of lidocaine administration
to the PVN and to test the hypothesis that PVN activity may restrain sodium appetite by
inhibiting neural activity in the OVLT (Figure 3.4C). A one-way ANOVA indicated that
cFos expression in the OVLT differed between treatment groups (F(2,21) = 34.47,
p<.001; n = 6 rats/treatment group, 4-6 sections per brain area).

Post-hoc tests

indicated that lidocaine further enhanced 20 ng AngII-induced cFos expression in the
OVLT (33.29±3.0 versus 54.60±3.0, p = .001), emulating the effects seen with DOC
pretreatment. Additionally, cFos expression in the PVN was reduced with lidocaine
pretreatment, illustrating reduced PVN activity (140.6±15.6 versus 88.5±3.5, p = .010).

DISCUSSION
	
  
Classic studies showed that AngII and adrenal steroids work cooperatively to
elicit a robust salt appetite when elevated concurrently, as occurs during hypovolemia
and sodium depletion (Epstein, 1982; Stricker, 1966; Stricker & Wolf, 1966; Stricker,
1971; Toth, Stelfox, & Kaufman, 1987). This potentiation of sodium appetite has been
observed in rats, pigeons and baboons and is not secondary to natriuresis or diuresis
(Fluharty & Epstein, 1983; Massi & Epstein, 1990; Shade et al., 2002). Experiments with
agonists and antagonists confirmed the validity of the “synergy hypothesis” in situations
in which the appetite was associated with elevated endogenous levels of AngII and
aldosterone (Sakai et al., 1986). The present experiments aimed to reveal the cellular
mechanisms and brain sites employed by the combined actions of aldosterone-AngII to
potentiate sodium appetite.

	
  

Our initial hypothesis was that DOC and AngII actions
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converge on the ERK1/2 signaling pathway, given that adrenal steroids can increase
AT1R expression (Harada et al., 2001; Mazak et al., 2004; Ullian et al., 1992) and
enhance their cellular signaling (Lemarie, Paradis, & Schiffrin, 2008; Lemarie et al.,
2009). However, the present behavioral and biochemical studies did not support this
hypothesis. Rather, a follow-up experiment found that IP3 signaling was necessary for
the behavioral cooperation, although it did not mediate the sodium appetite expressed
when either hormone alone. A subsquent functional neuroanatomy experiment showed
that the combined DOC and AngII treatment suppressed cFos expression in the PVN,
reduced neurosecretion of oxytocin, and augmented Fos expression in the OVLT. This
led to the novel hypothesis that DOC-induced suppression of oxytocin neural activity in
the PVN relieves inhibition in the OVLT to allow a robust sodium ingestions. Our results
with local lidocaine administration into the PVN, verified by a lack of AngII-induced cFos
expression in the PVN, support this proposal based on elevated sodium appetite and
cFos induction in the OVLT. Thus, the present studies implicate an inhibitory signal
arising from the oxytocin neurons in PVN which may target neurons in the OVLT.

Lack of support for an amplification of ERK1/2 signaling
As mentioned above, central AngII administration activates ERK1/2 in the SFO
and PVN

(Wei et al., 2009).

ERK1/2 signaling is specifically required for sodium

appetite after exogenous AngII treatment (Daniels et al., 2005) and treatment that trigger
endogenous AngII production (Felgendreger et al., 2013). Thus, we hypothesized that
ERK1/2 also would be critical for the cooperative effect of DOC and AngII on sodium
intake.

Behavioral pharmacology and signaling biochemistry experiments, while

replicating the previous finding of AngII-induced ERK1/2 and ERK1/2-dependent sodium
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appetite, did not support a role for ERK1/2 in the combined effect of DOC and AngII.

The interaction of DOC and AngII on IP3-mediate cFos induction
The AT1R is coupled with intracellular IP3 formation

(Beresford MJ, 1992;

Enjalbert et al., 1986; Smith et al., 1984; Taylor et al., 1990), which in turn acts on the
IP3 receptor on the endoplasmic reticulum to liberate intracellular calcium as a third
messenger

(Capponi, Rossier, & Vallotton, 1988; Nabika, Velletri, Lovenberg, &

Beaven, 1985; Suarez et al., 2002).

One consequence of calcium mobilization is

transcription of immediate early genes, including cFos (Clark et al., 1992; Daniels et al.,
2005; Jomphe et al., 2003; Templeton et al., 1998; W. Zhang et al., 2012). Central
administration of AngII activates cFos expression in several brain regions, including the
OVLT, SFO, PVN, and SON (Blackburn et al., 1992; Herbert, Forsling, Howes, Stacey,
& Shiers, 1992; McKinley et al., 1992), as replicated here. In agreement with previous
work (Blackburn et al., 1992), DOC pretreatment diminished AngII-induced cFos in the
PVN and oxytocin neurosecretion. The novel finding that DOC pretreatment increases
cFos expression in the OVLT represents a striking correlation with the behavioral effects
of DOC and AngII on sodium ingestion. The OVLT is included in the region referred to
as the anteroventral third ventricle (AV3V), and partial damage to this region disinhibits
sodium appetite (Andersson, Leksell, & Lishajko, 1975; Fitts, Tjepkes, & Bright, 1990;
Fitts, 1991; Gardiner, Jolley, Vagnucci, & Stricker, 1986). IP3 receptor activation was
necessary for the DOC and AngII cooperativity on sodium intake, without affecting the
sodium ingestion stimulated by either hormone alone.

Taken together, 1) the IP3

signaling pathway is uniquely necessary for the DOC and AngII cooperative effect on
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sodium appetite; 2) its downstream effector cFos is uniquely correlated with sodium
appetite in the OVLT; 3) PVN activity and oxytocin release are suppressed during the
cooperative stimulation of sodium appetite. A parsimonious explanation of these results,
partially supported by previous studies, would be that DOC treatment inhibits oxytocin
neurons in the PVN, which in turn relieves inhibition on a subset of OVLT neurons, which
then augment the drive for sodium ingestion based on IP3 signaling.

The role of oxytocin in sodium appetite
A model has been proposed in which centrally acting AngII simultaneously
stimulates and inhibits sodium appetite, with the inhibition caused by oxytocin release in
the brain (Blackburn et al., 1992; Stricker & Verbalis, 1987; Stricker & Verbalis, 1996).
Other investigators also have observed a disinhibition of sodium appetite after central
administration of an oxytocin antagonist or in knockout mice (Chow, Sakai, Fluharty, &
Flanagan-Cato, 1997; Fitts et al., 2003; Puryear, Rigatto, Amico, & Morris, 2001),
although the enhancement of the sodium appetite by an oxytocin antagonist may be
somewhat dependent on the dose of AngII (Fitts et al., 2003; Stricker & Verbalis, 2004).
The present results replicate several key findings, including the dampening of AngIIinduced cFos activation of the PVN and oxytocin release by DOC pretreatment.
However, the site of oxytocin action to inhibit sodium appetite remained unknown.
The finding that DOC treatment uniquely enhanced the effect of AngII on cFos
expression in the OVLT suggests that it is the target of the oxytocin-ergic inhibition of
sodium appetite. Indeed, oxytocin receptor mRNA is localized to the OVLT (Yoshimura
et al., 1993), and oxytocin axons project to the OVLT from the PVN (Buijs, 1978). The
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OVLT includes osmosensitive neurons and is thought to function as the brain’s primary
osmostat (Denton, McKinley, & Weisinger, 1996; Johnson, Cunningham, & Thunhorst,
1996).

Many neurons in the OVLT are excited by hypertonicity and inhibited by

hypotonicity (Honda, Negoro, Dyball, Higuchi, & Takano, 1990; Nissen, Bourque, &
Renaud, 1993; Sayer, Hubbard, & Sirett, 1984; Vivas, Chiaraviglio, & Carrer, 1990),
mediated by members of the transient receptor potential vanilloid proteins (Ciura &
Bourque, 2006). The OVLT sends both GABAergic and glutamatergic projections to a
variety of brain regions (Camacho & Phillips, 1981; Richard & Bourque, 1996), although
the functions of these projections remain ill-defined. The present results build on this
body of work by indicating that activation of the PVN normally inhibits a subpopulation of
OVLT neurons. Given that the natriorexic effect of PVN inhibition was reversed with
central oxytocin administration, oxytocin is likely the critical inhibitory signal arising from
the PVN. Thus, the OVLT, a key sensor of body fluid parameters appears to also be the
target of oxytocin modulation of sodium appetite.

Interpretational limitations
The present work focused on the OVLT, SFO, PVN and SON based on their
importance to DOC and AngII actions, based on previous studies. Brainstem, limbic,
gustatory, and other hypothalamic regions are certainly also involved, but their
contributions were beyond the scope of this study.

Previous tracing studies have

demonstrated a direct connection between the PVN and OVLT; however, the present
work did not address whether the changes in PVN activity directly or indirectly affects the
OVLT. Future studies are needed to examine those questions. Likewise, the analysis of
cFos expression and the pharmacological disruption of neural activity are not informative
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about the cascade of information processing within the broader neural network. Given
that many hypothalamic areas are reciprocally connected, further studies will be needed
to disambiguate the roles that these brain regions play in promoting and inhibiting
sodium appetite.

CONCLUSIONS
	
  
The present analysis has yielded several new insights towards understanding the
cooperativity of DOC and AngII to elicit a robust sodium appetite. First, these results
rule out the ERK1/2 signaling pathway as an underlying mechanism. Second, the OVLT
and PVN display divergent patterns of activation, suggesting that DOC relieves an
inhibitory signal from the PVN to the OVLT. Third, IP3 signaling is required for the
cooperativity of DOC and AngII. Fourth, local inhibition of the PVN mimics the effect of
DOC to enhance sodium appetite and activation of the OVLT. Additional work is needed
to reveal the broader network controlling sodium appetite, including downstream target
of OVLT activity and the upstream signals to the oxytocin neurons.
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Figure 3.1. Erk1/2 is not necessary for the DOC/AngII potentiation of sodium appetite.
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Panel A. Bar graphs illustrating the potentiation of AngII-induced sodium but not water intake by
DOC (n = 12/group). Panel B. Bar graphs illustrating the effect of blocking ERK1/2 activation on
DOC and AngII-induced sodium and water intake (n=18/group). DOC potentiated 2 and 20 ng
AngII-induced sodium intake. This behavior was not reduced by the MEK inhibitor U0126,
however, U0126 reduced sodium intake with 20 ng AngII alone. AngII-induced water intake was
not potentiated by DOC. Panel C. Bar graphs illustrating phosphorylated ERK1/2 levels in the
OVLT/SFO and PVN/SON after either oil or DOC pretreatment followed by icv treatments with 2
or 20 ng AngII (n = 6/group). AngII treatment induced significant ERK1/2 phosphorylation
compared to vehicle in both sets of brain regions. DOC pretreatment did not enhance this
activation. Representative western blot images of ERK1/2 phosphorylation are shown above
each quantified bar. For the sake of clarity, only specific statistical differences are highlighted.
The symbol “A” indicates AngII is different from vehicle; “B” indicates DOC/AngII is different from
AngII; “C” indicates U0126/AngII is different from AngII; “D” indicates U0126/DOC/AngII is
different from DOC/AngII, p<0.05. Abbreviations: AngII= Angiotensin II, DOC =
deoxycorticosterone acetate, p-ERK1/2 = phosphorylated extracellular signal-regulated kinase 1
and 2, OVLT = Organum vasculosum of the lateral terminalis, PVN = paraventricular nucleus of
the hypothalamus, SFO = subfornical organ, SON = supraoptic nucleus of the hypothalamus, Veh
= vehicle.
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Figure 3.2. DOC pretreatment enhanced AngII-induced OVLT activation and reduced PVN
activity and OT release.
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Panel A. Bar graphs illustrating cFos cell counts in different brain areas (OVLT, SFO, PVN, and
SON) after either vehicle or DOC pretreatment followed by icv vehicle or 20 ng AngII (n =
6/group). In the OVLT, each treatment condition induces cFos immunostaining compared with
vehicle; DOC/AngII induced additional cFos immunostaining. In the SFO, both AngII alone and
DOC/AngII induced more cFos staining than either vehicle or DOC alone. cFos labeling in the
PVN was increased by AngII, but DOC reduced the AngII-induced cFos expression to control
levels. In the SON, AngII induced cFos staining. Representative images of the OVLT and PVN
(coronal plane, 10x) in each treatment condition are shown above the bar graphs. Representative
images of SFO and SON are not shown, but similar data were seen. Panel B. Bar graphs
illustrating OT and AVP plasma levels after either vehicle or DOC pretreatment followed by icv
vehicle or 20 ng AngII (n = 8/group). AngII treatment increased OT levels, and this effect was
reduced by DOC pretreatment. However, AngII treatment elevated AVP levels, regardless of
pretreatment. For the sake of clarity, only specific statistical differences are highlighted. The
symbol “A” indicates AngII is different from vehicle; “B” indicates DOC/AngII is different from
AngII. Abbreviations: AngII = Angiotensin II, AVP = vasopressin, DOC = deoxycorticosterone
acetate, OT= oxytocin, OVLT = Organum vasculosum of the lateral terminalis, PVN =
paraventricular nucleus of the hypothalamus, SFO = subfornical organ, SON = supraoptic
nucleus of the hypothalamus, Veh = Vehicle
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Figure 3.3. The IP3 receptor is required for DOC/AngII potentiation of sodium appetite.
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Panel A. Bar graphs illustrating the level of cFos expression in the OVLT and SFO after vehicle,
XC, 20 ng AngII, or XC plus 20 ng AngII icv (n = 6/group). Representative images of cFos
staining of OVLT coronal sections (10x) in each treatment group are shown above the graphs.
Representative images of the SFO are not shown, but similar data were seen. AngII induced
cFos staining in both the OVLT and SFO, and the effect was reduced by XC. Panel B. Bar
graphs illustrating the effect of XC on DOC and 20 ng AngII induced sodium and water intake (n =
10/group). DOC potentiates AngII-induced sodium intake; this effect was impaired by the IP3
receptor inhibitor XC. XC did not affect sodium intake induced by AngII alone. AngII-induced
water intake was reduced by XC. For the sake of clarity, only specific statistical differences are
highlighted. The symbol “A” indicates AngII is different from vehicle; “B” indicates DOC/AngII is
different from AngII; “C” indicates XC/AngII is different from AngII; “D” indicates XC/DOC/AngII is
different from DOC/AngII, p<0.05. Abbreviations: AngII = Angiotensin II, DOC =
deoxycorticosterone acetate, OVLT = Organum vasculosum of the lateral terminalis, SFO =
subfornical organ, Veh = vehicle, XC = Xestospongin-C
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Figure 3.4. PVN inactivation enhances AngII-induced sodium appetite.
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Panel A. Illustration of rat coronal brain slices depicting bilateral guide cannula placements (filled
circles) above the PVN for lidocaine administration. Each pair of dots represents data from one
animal. Panel B. Bar graphs illustrating the effect of intra-PVN lidocaine on 20 ng AngII-induced
sodium and water intake (n = 10/group). Lidocaine treated animals increased their AngII-induced
sodium intake, but not water intake, mimicking the effects of DOC. Panel C. Bar graphs
illustrating cFos expression in the OVLT and PVN after vehicle, lidocaine, 20 ng AngII, or
lidocaine plus 20 ng AngII icv (n = 6/group). Representative images of cFos staining of OVLT
and PVN coronal sections (10x) in each treatment group are shown above the graphs. AngII
induced cFos immunostaining was enhanced by lidocaine in the OVLT and reduced in the PVN.
For the sake of clarity, only specific statistical differences are highlighted. The symbol “A”
indicates AngII is different from vehicle; “B” indicates lidocaine/AngII is different from AngII.
Abbreviations: AngII = Angiotensin II, OT = oxytocin, OVLT = Organum vasculosum of the lateral
terminalis, PVN = paraventricular nucleus of the hypothalamus, Veh = Vehicle.
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SUMMARY
	
  
Aldosterone and Angiotensin II (AngII) cooperate centrally to produce a robust
sodium appetite. Yet, it remains unknown how combined treatment with both hormones
affects mesolimbic circuits to selectively drive this ingestive behavior. We hypothesized
that treatment of aldosterone plus AngII enhances motivation for sodium, in part by
increasing

mesolimbic

activation.

To

test

this,

male

rats

pretreated

with

deoxycorticosterone (DOC; a synthetic precursor of aldosterone) and central AngII were
trained to press levers for either sodium or water. In a progressive ratio reinforcement
schedule, rats treated with both hormones exhibited a breakpoint ratio of sodium to
water that was three times higher than animals given either hormone alone. However,
AngII treatment augmented cFos levels in the ventral tegmental area and nucleus
accumbens,

regardless

of

DOC

pretreatment.

Lidocaine

inactivation

of

the

paraventricular nucleus, a treatment known to augment sodium appetite, enhanced the
ability of central AngII to increase cFos in these mesolimbic areas.

Lastly, DOC

increased levels of phosphorylated tyrosine hydroxylase immunoreactivity in the ventral
tegmental area, regardless of AngII treatment. Collectively, these results illustrate a
selective drive for sodium, prompted by the combination of AngII-induced mesolimbic
neural activity and DOC-induced dopamine synthesis.
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INTRODUCTION
	
  
Sodium homeostasis affects critical physiological functions such as extracellular
fluid volume, blood circulation, and neural activity (Weisinger et al., 1996).

Several

physiological mechanisms minimize sodium loss, and when it must be replaced, a robust
sodium appetite develops (Andersson, 1977). Parallel mechanisms contribute to sodium
appetite, including the renin-angiotensin-aldosterone system, an endocrine mechanism
that acts both peripherally and centrally to correct for sodium imbalance (Johnson &
Thunhorst, 1997). Reduced sodium levels, blood volume, or blood pressure triggers
renin production, which subsequently leads to increased circulating AngII and
aldosterone levels (J. O. Davis & Spielman, 1974; Denton et al., 1996). AngII acts in
the brain to induce both water intake and sodium intake, whereas aldosterone induces
solely sodium appetite, replacing lost fluids (Epstein et al., 1969). Suppression of either
central AngII or aldosterone actions does not entirely reduce sodium appetite in several
different experimental preparations, but blocking central actions of both hormones
completely abolishes the behavior

(Buggy & Jonklaas, 1984; Sakai et al., 1986).

Conversely, when both aldosterone and Angiotensin II (AngII) are given exogenously,
sodium appetite is potentiated beyond the additive effects of either hormone alone
(Fluharty & Epstein, 1983). This phenomenon has been observed in rats, pigeons and
baboons and is not secondary to natriuresis or diuresis (Massi & Epstein, 1990; Shade
et al., 2002). AngII and aldosterone bind to receptors in the subfornical organ and
nucleus of the solitary tract, respectively

(Ganong, 1984; Geerling et al., 2006).

However, the neural circuits that integrate aldosterone and AngII actions to augment
sodium appetite remain undefined.
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The interaction between aldosterone and AngII to potentiate sodium appetite
likely enhances activation of motivational circuits. Rats run faster towards a sodium
reward if both aldosterone and AngII are present compared to either hormone alone,
suggesting augmented behavioral drive (D. M. Zhang et al., 1984). Moreover, rats on a
sodium deficient diet, which increases aldosterone and AngII levels, choose sodium
ingestion over moderately reinforcing brain stimulation, indicating a common evaluative
mechanism (Conover, Woodside, & Shizgal, 1994; Stricker, Vagnucci, McDonald, &
Leenen, 1979).
Several reports indicate neuroanatomical connections between osmosensitive
brain areas and the mesolimbic system (Lucas, Grillo, & McEwen, 2007; Shekhtman et
al., 2007).

The mesolimbic dopamine system processes natural rewards, including

sodium after sodium loss (Roitman et al., 2002). Dopamine neurons in the ventral
tegmental area project to the nucleus accumbens, which projects to brain regions such
as the ventral pallidum to generate goal directed movement (Carelli, 2002). Thus, it is
feasible that aldosterone and AngII integration may involve activation of the ventral
tegmental area and nucleus accumbens in potentiating sodium appetite.

Moreover,

AngII and aldosterone elevate markers of dopamine release in the nucleus accumbens
(Axelrod, 1971; Roitman et al., 1999). For example, sodium depletion alters levels of
dopamine transporters and opioid peptides in the nucleus accumbens (Grondin, GobeilSimard, Drolet, & Mouginot, 2011; Lucas, Grillo, & McEwen, 2003).

Furthermore,

sodium appetite has been associated with changes in the dendritic arbor of ventral
striatum neurons (Roitman, Na, Anderson, Jones, & Bernstein, 2002). Though studies
have suggested a role for mesolimbic activity in sodium appetite, evidence for neural
activation and dopamine synthesis is lacking. Additionally, the effect of aldosterone and
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AngII cooperativity on mesolimbic activation has not been studied.
To examine the effect of combined aldosterone and AngII action in driving
sodium ingestion, rats were treated with either Vehicle/Vehicle, DOC/Vehicle,
Vehicle/AngII, or DOC/AngII and tested on a progressive ratio reinforcement schedule.
Whereas other studies measured reward by running speed or pressing a single lever for
sodium, which may be confounded with motor activation, our progressive ratio
experiment measured the motivational choice for sodium compared with water.
Mesolimbic neuronal activation was assessed by cFos expression in the ventral
tegmental area and nucleus accumbens after hormone treatments. In addition, levels of
tyrosine hydroxylase, a rate limiting enzyme for dopamine synthesis, was examined in
the ventral tegmental area and nucleus accumbens after hormone treatments.

We

hypothesized that aldosterone and AngII cooperatively enhance neuronal activation and
tyrosine hydroxylase activation in the ventral tegmental area and nucleus accumbens,
augmenting motivation for sodium. Overall, these experiments determine if aldosterone
and AngII integrate information through mesolimbic circuitry to exert a robust sodium
appetite.

MATERIALS AND METHODS
	
  
Animals
Adult male Sprague-Dawley rats (n = 61) that weighed between 225-250 g were
obtained from Charles River Laboratories (Wilmington, MA, USA).

Rats were pair-

housed in plastic tubs with standard bedding and with food and water available ad
libitum, except during experimental procedures. The temperature in the colony was
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maintained at 22 °C with a 12:12 h reversed light/dark cycle. Animals were allowed at
least one week to acclimate to the colony before any procedures were performed. The
Institutional Animal Care and Use Committee of the University of Pennsylvania approved
all procedures with animals.

Surgery
Surgeries were performed in aseptic conditions. Animals were anesthetized with
isofluorane gas before being fixed in a stereotaxic frame and implanted with a 26-gauge
guide cannulae (Plastics One, Roanoke, VA, USA) aimed at the lateral ventricle. For the
lateral ventricle surgeries, coordinates were: 0.48 mm caudal to bregma, 1.6 mm from
mid-line and 4.2 mm ventral to dura mater. For a subset of animals, an additional 26gauge double guide cannula (0.8 mm apart) was implanted into the paraventricular
nucleus (PVN). For PVN double cannula, coordinates were: 1.8 mm caudal to bregma,
0.4 mm from the mid-line and 7.7 mm ventral to dura mater. These coordinates were
chosen to allow an internal injection cannula to extend beyond the guide cannula into
either the ventricular space or the PVN itself. The cannulae were fixed in place with
dental cement and bone screws, and the animals were allowed at least five days to
recover before verification procedures were performed.

After surgery, animals were

injected with yohimbine (0.11 mg/kg, Ben Venue Laboratories Bedford, OH).

Upon

awakening, animals were singly housed.
Five days after surgery and prior to undergoing experimental treatments, animals
were tested for correct lateral ventricle cannula placement and patency. They were
given an icv injection of 20.0 ng of AngII diluted in aCSF via a Hamilton syringe
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connected with PE-10 tubing to an injector that terminated 1 mm beyond the guide
cannula. Animals were excluded from the experiment if they failed to demonstrate a
drinking response in less than 30 seconds, consuming at least 3 ml of water, in two
separate AngII challenges. Animals began behavioral testing three days after the icv
test injections.

Experimental Design
In all experiments, animals were assigned to one of four treatments in a 2 x 2
crossover design. Animals were first pre-treated twice daily (10 hours apart) for three
days with a subcutaneous injection of either sesame oil or Deoxycorticosterone Acetate
(DOC; .25 mg/.2 ml sesame oil; Sigma, St Louis, MO). DOC is typically used instead of
aldosterone because it penetrates the blood brain barrier more easily than Aldo due to
its low capacity for hydrogen bond formation (Kraulis, Foldes, Traikov, Dubrovsky, &
Birmingham, 1975). Animals were then injected icv with either artificial cerebrospinal
fluid (aCSF; R&D Systems, Minneapolis, MN) or 20.0 ng AngII in a volume of 2.0 ul
(Bachem, King of Prussia, PA). The treatment groups will be referred to as follows:
Vehicle/Vehicle, DOC/Vehicle, Vehicle/AngII, DOC/AngII.

Experiment 1. Progressive Ratio Task
Rats acclimated in wire mesh cages for one hour to two 25-ml bottles containing
tap water and 3% saline, each marked with 0.2 ml graduations. The saline bottle was
then removed, and rats were water restricted for 23 hours per day for the next six days.

	
  

	
  
84	
  

During the six days, rats underwent operant lever pressing training in conditioning boxes
for 30 minutes per day (Med Associates; MDPC IV Software, St. Albans, Vermont). The
conditioning boxes contained levers for both water (right lever) and 3% saline (left lever).
During the first two training days, a fixed ratio (FR1) autoshaping procedure was
employed (each lever press earned a 0.1 ml water or saline reward, depending on which
of the two levers was pressed; a free liquid reward was dispensed every 300 sec that
elapsed without reinforcement).

The animals then received 2 training days of FR1

schedule without autoshaping, followed by 2 training days of FR3 training. After learning
the task, rats were given ad libitum access to water again. Rats were then assigned to
treatment groups as discussed above in Experimental Design, and given a break
operant lever pressing training while they received their three days of pretreatment
injections. After pretreatment was complete, rats were administered their assigned icv
injection, and immediately given a test with a progressive ratio (PR) reinforcement
schedule. The response requirement of the PR schedule increased progressively as
previously described (J. F. Davis et al., 2011). The breakpoint for each animal was
defined as the final completed requirement that preceded a 10 minute period without
earning a reinforcer, with a two hour limit total. Food was not available during testing.

Experiment 2: Hormone-Induced cFos expression
To observe brain activation after DOC and AngII treatments, rats were assigned
to treatment groups as discussed above in Experimental Design.

To observe brain

activation after lidocaine and AngII treatment, rats were administered lidocaine into the
PVN (8.5 nmol/side of 2% lidocaine in a volume of 0.4 ul; Phoenix Pharmaceuticals,
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Burlingame, CA), followed five minutes later by 20 ng AngII icv. Sixty minutes after the
last icv injection in each study, each rat was anesthetized with 50 mg/kg ketamine and
20 mg/kg xylazine, intraperitoneally (ip). They were perfused transcardially with 100 mL
of heparinized saline followed by 200 mL 4% paraformaldehyde (Electron Microscopy
Sciences,

Fort

Washington,

PA).

The

brains

were

isolated,

post-fixed

in

paraformaldehyde overnight at 4°C, then submerged in 20% sucrose in .1M phosphate
buffer for three days. Coronal sections were cut on a freezing microtome into three
serial sets of 40-um-thick sections. These slices encompassed the ventral tegmental
area as well ass the shell and core of the nucleus accumbens. One set from each animal
underwent immunohistochemical staining and analysis.
Sections were washed in Tris-buffered saline (TBS; pH 7.4) then incubated with
a cFos antibody (1:500, sc-52, rabbit; Santa Cruz Biotechnology, Santa Cruz, CA) in
TBS with .2% TritonX-100 and 3% normal donkey serum (Jackson Immunoresearch;
West Grove, PA) overnight at 4°C. After several washes, sections were incubated with a
Biotin-SP-conjugated

AffiniPure

Donkey

Anti-rabbit

IgG

(1:100,

Jackson

Immunoresearch) in TBS with .2% TritonX-100 and 3% normal donkey serum for 2
hours at room temperature. After several washes, sections were incubated with the
Vectastain ABC kit (Vector Laboratories, Burlingame, CA) for one hour.

This was

followed by another set of washes before staining with 3’3’-diaminobenzidine (SigmaAldrich) for 10 minutes. After a final set of washes, sections were mounted on slides,
air-dried, and cover slipped with DPX mounting media (Electron Microscopy Sciences:
Fort Washington, PA).
Images were acquired with a digital camera (Diagnostic Instruments, Sterling
Heights, MI, model RTKE), maintaining the same microscope and camera settings to
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ensure the same level of light and exposure for all images. Background was subtracted
from images using Photoshop, and images were thresholded to the same level (200).
Images were further analyzed in NIH Image J using standardized boxes for each brain
region (calculated using Paxinos & Watson Rat Brain Atlas), using the analyze particles
function. Pixel size minimum was 15 and circularity was set to 0.35.

Experiment 3: Hormone Regulation of Tyrosine Hydroxylase
Animals were assigned to treatment groups as described above in Experimental
Design. Five minutes after the last injections, animals were rapidly decapitated and
brains were flash frozen in hexane over dry ice. The five minute time point was selected
based on its correlation with a significant increase in lever presses for sodium in the
progressive ratio experiment.

Using a cryostat, 1 mm punches of brain regions of

interest (ventral tegmental area, nucleus accumbens shell and core) were collected from
300 µm slices. Punches were immersed in lysis buffer containing 25 mM Tris-HCl (pH
8), protease inhibitors (pepstatin, leupeptin, aprotinin), and phosphatase inhibitors
(sodium pyrophosphate, sodium fluoride, sodium molybdate, phenylarsin oxide, and
sodium orthovanadate). The ventral tegmental and nucleus accumbens (shell and core)
punches were immersed in 50 and 100 uL of lysis buffer, respectively. Brain punches
were sonicated for three seconds followed by centrifugation at 14,000 rpm in 4°C for 15
minutes. Supernatant was collected and a Bicinchoninic acid (BCA) protein assay was
performed on five microliters of each sample. Based on the protein levels detected by
BCA, appropriate amounts of sample and sample buffer were loaded into wells of a 10%
sodium dodecyl sulfate polyacrylamide gel. Western blot for phospho- and total TH was
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performed using the LiCor Odyssey System. The following antibodies were used:
monoclonal anti-tyrosine hydroxylase antibody T2928 at 1:8000 (Sigma Aldrich); tyrosine
hydroxylase pS31 rabbit polyclonal antibody #36-9900 at 1:400 (Life Technologies,
Carlsbad, CA); IRDye 800CW Goat anti-Mouse IgG (H + L) 926-32210 at 1:2000 (Li-Cor
Biosciences, Lincoln, NE); IRDye 680LT Goat anti-Rabbit IgG (H + L) 926-68021 at
1:4000 (Li-Cor Biosciences).

Statistical Analysis
Data are presented as the mean ± the standard error of the mean.

For all

experiments, comparisons were made between treatment groups with a two-way
ANOVA. When warranted, planned comparison post-hoc t-tests were performed. All
hypothesis tests used α=0.05 as the criterion level of significance. Statistical analyses
were conducted using Prism 2.0 software (La Jolla, CA) for one-way or two-way
ANOVAs.

RESULTS
	
  
Experiment 1: The Progressive Ratio Task
The progressive ratio task was used to determine if aldosterone and AngII shift
the effort rats are willing to exert for sodium ingestion. Rats were pretreated with either
oil or DOC, followed by icv treatments of vehicle or AngII and allowed to press levers:
one for access to 3% saline and the other for access to water. Figure 4.1A illustrates the
number of lever presses over time for 3% saline and water. Visual inspection suggests a
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difference based on treatment, with DOC/AngII treated rats pressing more for 3% saline
than all other treatment groups. Although the Vehicle/AngII group pressed more for
water, the DOC/AngII-treated rats pressed very little for water, and for the shortest
amount

of

time

(Vehicle/Vehicle:

14.0±3.5

min,

DOC/Vehicle:

Vehicle/AngII: 23.4±5.7 min, DOC/AngII: 11.2±3.0 min).

18.6±3.7

min,

The total number of lever

presses for both 3% saline and water for each treatment group is quantified in bar
graphs in Figure 4.1B. A two-way ANOVA established a main effect for AngII (F(1,29) =
13.9, p<0.001) but not DOC (F(1,29) = 0.101, p = 0.752) on 3% saline lever presses,
and a trend for an interaction between the two treatments (F(1,29) = 2.3, p = 0.138; n =
6 rats/treatment group). Bonferonni post-hoc t tests revealed that the DOC/AngII group
pressed significantly more on the saline lever compared with the Vehicle/Vehicle and
DOC/Vehicle groups (Vehicle/Vehicle: 10.9±2.4 presses, DOC/Vehicle: 6.4±1.7 presses,
Vehicle/AngII: 19.1±6.4 presses, DOC/AngII: 26.0±2.8 presses; p<0.01).

A two-way

ANOVA established a main effect for AngII (F(1,29) = 5.73, p = 0.023) but not DOC
(F(1,29) = 1.69, p = 0.203) on water lever presses, and a significant interaction between
the two hormones (F,29) = 8.35, p = 0.007). Bonferonni post-hoc t tests revealed that
rats treated with Vehicle/AngII pressed more for water than any other treatment group
(Vehicle/Vehicle: 16.9±5.2 presses, DOC/Vehicle: 29.5±4.9 presses, Vehicle/AngII:
58.9±10.7 presses, DOC/AngII: 25.5±8.9 presses; p<0.01).
With a progressive ratio schedule of reinforcement, the response requirement to
attain rewards increases according to the same rule throughout the test session until the
rat stops responding (Sclafani & Ackroff, 2003). The highest ratio completed is referred
to as the breakpoint ratio and provides a measure of reinforcement.

Figure 4.1C

illustrates the breakpoint ratio of sodium to water for each treatment group, allowing us
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to compare the amount of effort exerted to receive a sodium reward versus a water
reward. A 2-way ANOVA established a main effect for AngII, DOC, and an interaction
between the two (F(1,29) = 4.59, p = 0.046; F(1,29) = 3.94, p = 0.0568; F(1,29) = 8.59, p
= 0.006). Bonferonni post-hoc t tests revealed that DOC plus AngII treated rats had a
significantly higher sodium to water breakpoint ratio than all other treatment groups
(Vehicle/Vehicle: 0.8±0.1, DOC/Vehicle: 0.3±0.1, Vehicle/AngII: 0.4±0.1, DOC/AngII:
2.7±0.9, p<0.05). Together, these data indicate that when both aldosterone and AngII
are present, rats are uniquely motivated to press for sodium compared to water.

Experiment 2: Hormone-Induced cFos expression
DOC/AngII cFos expression
Upon observing an increased sodium:water breakpoint ratio after DOC/AngII
treatment, we examined activation in key brain areas that may underlie this change in
motivation. As shown in Figure 4.2, the number of cFos labeled cells was quantified in
the ventral tegmental area and the nucleus accumbens after Vehicle/Vehicle,
DOC/Vehicle, Vehicle/AngII, and DOC/AngII treatment. A 2-way ANOVA revealed a
main effect for AngII and DOC, but not for an interaction between the two hormones in
the ventral tegmental area (F(1,8) = 49.63, p<0.001, F(1,8) = 6.25, p = 0.037, F(1,8) =
0.43, p = 0.527, respectively). Bonferonni corrected t tests indicated that Vehicle/AngII
and

DOC/AngII

increased

cFos

expression

compared

to

Vehicle/Vehicle

(Vehicle/Vehicle: 72.6±12.3 versus DOC/Vehicle: 93.4±5.4, Vehicle/AngII: 129.0±4.3,
DOC/AngII: 143.5±11.5, p = 0.170, p<0.05, p<0.05, respectively.).

However,

pretreatment with DOC did not significantly enhance AngII-induce cFos. In the nucleus
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accumbens core, a 2-way ANOVA revealed a main effect for AngII, but no effect for
DOC or their interaction on cFos expression (F(1,9) = 9.05, p = 0.014; F(1,9) = 4.17, p =
0.071; F(1,9) = 0.11, p = 0.749, respectively). Bonferonni post-hoc tests indicated that
Vehicle/AngII and DOC/AngII treatments increased cFos levels compared to
Vehicle/Vehicle (Vehicle/Vehicle: 14.5±4.2 versus DOC/Vehicle: 23.3±1.9, Vehicle
/AngII: 27.5±0.8, DOC/AngII: 34.9±8.8; p = 0.119, p<0.010, p<0.050, respectively).
Again, DOC pretreatment did not significantly enhance AngII-induced cFos expression in
the core. Lastly, a 2-way ANOVA for the nucleus accumbens shell revealed a main
effect for AngII, but no effect for DOC or the two-hormone interaction on cFos
expression (F(1,9) = 13.63, p = 0.005, F(1,9) = 2.89; p = 0.123; F(1,9) = 0.59, p = 0.462).
Bonferonni post-hoc t tests indicated that each treatment group induced significant cFos
expression compared to vehicle (Vehicle/Vehicle: 13.0±5.6, versus DOC/Vehicle:
23.5±0.6, Vehicle/AngII: 33.1±0.9, DOC/AngII: 38.9±10.1; p<0.05, p<0.01, p<0.05,
respectively). Similar to both the ventral tegmental area and core of the accumbens,
DOC pretreatment did not significantly enhance AngII-induced cFos expression in the
shell. To summarize, AngII induced significant cFos expression in the ventral tegmental
area and nucleus accumbens, but DOC pretreatment did not significantly enhance this
activation.

PVN-lido/AngII cFos expression
We next used another preparation of enhanced sodium appetite to examine its
effect on cFos activation in these key mesolimbic brain areas. Previous data from our
lab suggests that DOC enhances AngII-induced sodium appetite through inactivation of
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the PVN. In particular, inactivation of the PVN with lidocaine (PVN-lido) mimicked the
effect of DOC by enhancing AngII-induced sodium appetite.

In Figure 4.3, cFos

expression was examined in the ventral tegmental area and nucleus accumbens after
PVN-lido/AngII treatment.

cFos expression in the VTA differed between treatment

groups (F(2,8) = 19.02, p<0.001).

AngII increased cFos expression compared to

Vehicle, and PVN-lido pretreatment further enhanced this activation (Vehicle/Vehicle:
68.0±7.0 versus Vehicle/AngII: 159.3±12.3, PVN-lido/AngII: 203.6±13.4; p<0.01,
p<0.05). cFos expression in the nucleus accumbens core also differed between
treatment groups (F(2,12) = 11.49, p<0.01).

Analogous to the VTA, post-hoc tests

revealed that AngII induced significant cFos expression in the core compared to Vehicle.
Moreover, PVN-lido further enhanced this activation (Vehicle/Vehicle: 14.8±0.5 versus
Vehicle/AngII: 33.4±3.2, Lidocaine/AngII: 43.7±3.0; p<0.05, p<0.05). cFos expression in
the nucleus accumbens shell differed between treatment groups (F(2,12) = 9.87,
p<0.01). Post-hoc t tests indicated that AngII and PVN-lido/AngII both increased cFos
expression compared to Vehicle, however, PVN-lido did not further enhance levels
beyond AngII alone (Vehicle/Vehicle: 15.0±1.0, Vehicle/AngII: 36.3±3.0, Lidocaine/AngII:
42.3±3.1; p<0.01, p<0.01, p = 0.22). In summary, PVN-lido treatment enhances AngIIinduced cFos expression in the ventral tegmental area and nucleus accumbens core.

Experiment 3: Hormone Regulation of Tyrosine Hydroxylase
Hormone-induced increases in neural activation would logically also involve an
increase in dopamine activity in the ventral tegmental area and accumbens. To test this,
we quantified tyrosine hydroxylase activity, likely indicating dopamine release, in these
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brain areas. Rats were pretreated with vehicle or DOC followed by icv injections of
vehicle or AngII, and tissue was collected five minutes after the last injection. As shown
in Figure 4.4, tyrosine hydroxylase levels (panel A) and phosphorylated tyrosine
hydroxylase levels (panel B) were examined in the ventral tegmental and nucleus
accumbens.

A 2-way ANOVA revealed a main effect for both DOC and AngII on

tyrosine hydroxylase expression in the ventral tegmental area (F(1,8) = 16.6, p<0.01;
F(1,8) = 6.0, p<0.05).

Post hoc tests indicated each treatment group significantly

enhanced tyrosine hydroxylase expression compared to vehicle (Vehicle/Vehicle:
2.6±1.1, DOC/Vehicle: 13.5±1.1, Vehicle/AngII: 10.2±2.2, DOC/AngII: 15.8±3.0; p<0.05,
p<0.01, p<0.05). However, DOC pretreatment did not significantly enhance the effects
of AngII on tyrosine hydroxylase expression. In the core of the nucleus accumbens,
each treatment only resulted in trends for increasing tyrosine hydroxylase. However, in
the shell of the nucleus accumbens, DOC but not AngII had a main effect, and there was
a trend for their interaction on tyrosine hydroxylase expression (F(1,8) = 9.3, p<0.01;
F(1,8) = 1.0, p = 0.35; F(1,8) = 4.8, p = .059, respectively). Post-hoc t tests revealed
DOC increased tyrosine hydroxylase levels significantly (Vehicle/Vehicle: 8.4±1.8,
DOC/Vehicle: 13.9±0.2, Vehicle/AngII: 11.7±0.8, DOC/AngII: 12.7±0.7, p<.05).

In

summary, DOC treatment induces tyrosine hydroxylase expression in the ventral
tegmental area and nucleus accumbens shell.
DOC may induce more tyrosine hydroxylase expression, but it is the level of
phosphorylation that indicates the amount of activated enzyme to synthesize dopamine.
In the ventral tegmental area, a 2-way ANOVA revealed a main effect for DOC, and not
AngII (F(1,8) = 23.5, p<0.01); F(1,8) = 0.8, p = 0.38) on tyrosine hydroxylase
phosphorylation.
	
  

Post hoc t tests indicated DOC pretreatment increased tyrosine
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hydroxylase activation, but AngII treatment did not (Vehicle/Vehicle: 0.4±0.3,
DOC/Vehicle: 5.6±1.8, Vehicle/AngII: 1.6±0.8, DOC/AngII: 6.2±0.4; p<0.045, p = 0.23,
p<0.001). Similarly, DOC pretreatment conditions significantly increased tyrosine
hydroxylase phosphorylation compared to vehicle in the core of the nucleus accumbens
(Vehicle/Vehicle: 0.3±.3, DOC/Vehicle: 5.2±0.6, Vehicle/AngII: 4.0±1.1, DOC/AngII:
5.1±0.6, p<0.01, p = 0.08, p<0.01). However, a 2-way ANOVA revealed a main effect for
DOC, trend for AngII, and a significant interaction between the two hormones on tyrosine
hydroxylase phosphorylation in the accumbens shell (F(1,7) = 31.7, p<0.001; F (1,7) =
4.2, p = 0.08; F(1,7) = 19.8, p<0.01).

Post hoc tests revealed that each treatment

increased phosphorylation of the enzyme compared to vehicle, but DOC pretreatment
did not significantly enhance phosphorylation compared to AngII alone (Vehicle/Vehicle:
0.7±0.6, DOC/Vehicle: 6.3±0.2, Vehicle/AngII: 4.4±0.5, DOC/AngII: 5.0±0.7; p<0.01,
p<0.05, p<0.05). In summary, DOC pretreatment increased phosphorylation levels of
tyrosine hydroxylase in the ventral tegmental area and accumbens, while AngII only had
an effect in the shell of the accumbens.

DISCUSSION
	
  
AngII and aldosterone increase the willingness to work for sodium. For example,
classic studies demonstrate that rats run faster to receive a sodium reward if both
aldosterone and AngII are present compared with either hormone alone (D. M. Zhang et
al., 1984). The mesolimbic dopamine system is known to be involved in generating goal
directed movement, including sodium ingestion after depletion (Carelli, 2002; Roitman et
al., 2002). These experiments aimed to define changes in motivation and mesolimbic
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activity underlying sodium appetite when aldosterone and AngII are present.

Our

behavioral studies indicated that when both aldosterone and AngII are present, rats are
highly motivated to press levers for sodium compared to water.

Functional

neuroanatomical studies showed increased activation in the nucleus accumbens and
ventral tegmental area after AngII treatment, but DOC pretreatment did not significantly
enhance this effect. However, PVN inactivation by lidocaine did enhance AngII-induced
mesolimbic activation in the ventral tegmental area and core of the accumbens.
Contrarily, tyrosine hydroxylase activation in the ventral tegmental area is mainly due to
DOC pretreatment. Thus, the present studies implicate a selective drive for sodium,
prompted by the combination of AngII-induced mesolimbic neural activity and DOCinduced dopamine synthesis.

Increase in motivation for sodium
Under normal conditions, a rat will avoid concentrated sodium solutions
(Berridge, Flynn, Schulkin, & Grill, 1984). However, when stimulated by RAAS, rats will
exhibit robust sodium appetite for these same solutions, as demonstrated in our
progressive ratio studies.

Progressive ratio schedules are widely used to measure

incentive value, as the response requirements to obtain reinforcements increases
according to the same rule until the rat stops responding; the highest ratio completed,
the breakpoint, provides a measure of reinforcer value

(Sclafani & Ackroff, 2003).

Progressive ratio schedules emulate some aspects of foraging: resources are depleted
in a given area the more they are consumed, so they become increasingly more difficult
to find (Starr & Rowland, 2006). While some studies have used this method to examine
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sodium appetite after depletion, our experiments allowed us to compare how AngII and
aldosterone influence effort-value for both sodium and water. Our studies revealed a
dramatic shift in behavior with DOC/AngII treatment: the breakpoint ratio for sodium
compared to water increased significantly for those rats treated with both hormones
versus either hormone alone. Although AngII typically stimulates a high ratio of water to
saline intake (Prakash & Norgren, 1991), pretreatment with DOC considerably alters
behavior such that rats are more motivated to work for sodium than water when both
hormones are present. While the initial separate targets of aldosterone and AngII are
known, the downstream integration areas remain undefined. However, several reports
indicate neuroanatomical connections between osmosensitive brain areas and the
mesolimbic dopamine system (Lucas et al., 2007; Shekhtman et al., 2007). Although
the precise role of dopamine remains in question, studies depleting rats of dopamine
with 6-hydroxydopamine indicated that dopamine systems are necessary for motivation,
but do not participate in the hedonic pleasure (Berridge & Robinson, 1998).

The role of mesolimbic activity in sodium appetite
The mesolimbic dopamine system, which contains dopaminergic neurons in the
ventral tegmental area that project to the nucleus accumbens, is implicated in regulating
sodium appetite (Carelli, 2002; Roitman et al., 2002).

Our finding that DOC/AngII

increased motivation for sodium, as demonstrated by lever pressing in the progressive
ratio experiment, further implicated the mesolimbic dopamine system. However, the
functional neuroanatomical studies revealed cFos activation in both the ventral
tegmental area and nucleus accumbens depended on AngII but not DOC treatment. In
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effect, these data suggest that treatment with both hormones does not enhance
neuronal excitability in these brain areas, and therefore cannot fully explain the increase
in motivation for sodium. Suprisingly, lidocaine in the PVN did enhance AngII-induced
activation in these brain regions, implying that this preparation of enhanced sodium
appetite does not in fact mimic that of DOC/AngII. It is possible that cFos expression is
not a good measure of DOC effects, as injections of DOC are given for days in advance,
and not perfectly timed to maximal cFos expression (Sagar, Sharp, & Curran, 1988).
This is in contrast to lidocaine injections, which took place minutes before AngII injection,
and thereby roughly an hour before cFos expression.
AngII-induced cFos expression in the mesolimbic areas is likely the result of
transynaptic activation. The ventral tegmental area does not have AngII receptors, so it
is not possible for this to be the primary site of activation (Brown, Steward, Ge, &
Barnes, 1996). In addition, lesions in initial brain targets that synapse onto the ventral
tegmental area ablate sodium appetite, indicating that upstream brain areas are
activated and required for this behavior

(Fitts et al., 2004).

Cells activated with

DOC/AngII treatment compared to AngII alone may be specific to motivation for sodium,
given that the combination of these hormones only potentates sodium intake. However,
concentrated nuclear staining on these brain sections makes this discrimination difficult.
Since cells were not double labeled for neural or dopaminergic markers, the cell types
activated are unknown; however, in the ventral tegmental area, the majority of neurons
present are dopaminergic (Oades & Halliday, 1987). Normally, the accumbens would
next integrate neural signals and organize the motivated behavior (Cardinal, Parkinson,
Hall, & Everitt, 2002), however, these rats did not ingest reinforcements before their
brains were examined. In studies that allowed rats access to salt after depletion, the
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nucleus accumbens shell rather than the core was more highly activated (Lucas et al.,
2003).

As the rats did not have access to sodium, significant differences in cFos

activation between the shell and core of the accumbens were not observed.

The role of tyrosine hydroxylase in sodium appetite
An increase in neural activation in the mesolimbic system likely includes
enhanced dopaminergic activity. This may involve increases in tyrosine hydroxylase, a
rate-limiting enzyme for dopamine synthesis that is mainly located in the soma of
dopamine neurons in the ventral tegmental area, but can be axonally transported into
the terminals projecting to the nucleus accumbens (Pickel, Joh, & Reis, 1975). Our
results indicate that aldosterone treatment increases tyrosine hydroxylase expression in
the ventral tegmental area and nucleus accumbens shell. Aldosterone was injected for
three days before collecting tissue; this time frame is conducive to gene transcription,
explaining the increase in tyrosine hydroxylase expression. However, AngII, given only
five minutes before enzyme levels were quantified, significantly increased the enzyme in
the ventral tegmental area. Though the timeline may appear brief, our findings are in
agreement with a study examining tyrosine hydroxylase levels during conditioned place
preference for morphine-related cues: these authors demonstrate increased tyrosine
hydroxylase activity in the ventral tegmental area within five minutes of the task (Liang et
al., 2012).
Besides increases in tyrosine hydroxylase expression, there may be more Ser31
phosphorylation of the enzyme, which augments catalytic activity and allows synthesis of
dopamine
	
  

(Colby, Thompson, & Patrick, 1989).
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Aldosterone treatment increases

tyrosine hydroxylase phosphorylation in both the ventral tegmental area and nucleus
accumbens, likely indicating more dopamine production.

Dopamine release in the

nucleus accumbens is correlated with both appetitive and consummatory aspects in
natural reward paradigms (Roitman, Stuber, Phillips, Wightman, & Carelli, 2004). Our
studies indicate that aldosterone primes the mesolimbic system by increasing tyrosine
hydroxylase activity, whereas AngII rapidly increases neuronal activity. Together, these
hormones may result in enhanced accumbal dopamine, which would correlate with the
increase in lever presses for sodium after DOC/AngII treatment in the progressive ratio
task. Through multiple techniques, we have demonstrated that aldosterone and AngII
together result in selective drive for sodium, which is associated with AngII-induced
increases in mesolimbic neural activity and aldosterone- induced increases in dopamine
synthesis.

The neural modules of sodium appetite
AngII acts initially on AT1R in circumventricular organs, such as the SFO and
OVLT (Lind, Swanson, & Ganten, 1984; McKinley et al., 1992; Tanaka, Kaba, Saito, &
Seto, 1986; Weiss & Hatton, 1990).

The OVLT is known to project to the lateral

hypothalamus (Camacho & Phillips, 1981).

Moreover, studies have revealed that

orexinergic neurons in the lateral hypothalamus project to and modulate dopaminergic
neurons in the ventral tegmental area, which then projects to the nucleus accumbens
(Fadel & Deutch, 2002; Narita et al., 2006).

For instance, injection of a dopamine

receptor antagonist into the lateral hypothalamus abolishes sodium appetite, whereas
stimulation of the lateral hypothalamus stimulates dopamine release, enhancing sodium
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appetite (Hoebel, Hernandez, Schwartz, Mark, & Hunter, 1989; Liedtke et al., 2011). As
the VTA does not contain AT1R, these connections would explain how AngII enhances
the release of striatal dopamine in freely moving rats within minutes, which then is
associated with an increase in drinking behavior (Brown et al., 1996; Hoebel, Rada,
Mark, & Hernandez, 1994).
Although there are mineralocorticoid receptors present in the ventral tegmental
area and nucleus accumbens, it is unlikely that this is the mechanism by which
aldosterone affects mesolimbic activity.

The available literature suggests that

mineralocorticoids act initially on NTS neurons, which contains HSD2 enzymes to
inactivate the much more highly concentrated glucocorticoids in the brain (Geerling &
Loewy, 2008). It is through both direct and indirect synaptic connections to the VTA that
aldosterone may affect dopaminergic activity. The indirect connections consist of an
NTS projection to the PVN, possibly via the BNST, which then projects to the OVLT,
where interaction with AngII may be possible. Whether it is at the OVLT, or VTA just
downstream, AngII and aldosterone eventually integrate their actions to cause this
potentiation in sodium appetite. Our data suggests that the combination of AngII and
aldosterone increases mesolimbic neuronal activation and tyrosine hydroxylase activity
prompting a selective drive for sodium.
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Figure 4.1. DOC/AngII treatment increases motivation for sodium.
Panel A. Line graphs illustrating cumulative presses over time for 3% Saline and Water after
Vehicle, DOC, AngII, or DOC plus AngII treatments (n = 12/group). Panel B. Bar graphs
illustrating total lever presses for 3% saline and water after Vehicle, DOC, AngII, or DOC plus
AngII treatments (n=12/group). DOC plus AngII treatment increased sodium presses while AngII
alone increased water presses. Panel C. Bar graphs illustrating the breakpoint ratio of sodium to
water after Vehicle, DOC, AngII, or DOC plus AngII (n = 12/group). DOC plus AngII causes the
highest sodium to water breakpoint ratio. Abbreviations: AngII= Angiotensin II, DOC =
deoxycorticosterone acetate, Veh = vehicle.
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Figure 4.2. DOC/AngII treatment increases cFos expression in the ventral tegmental area
and nucleus accumbens.
Bar graphs illustrating cFos cell counts in the ventral tegmental area and nucleus accumbens
core and shell after either vehicle or DOC pretreatment followed by icv vehicle or AngII (n =
12/group). AngII and DOC/AngII treatment increased cFos expression in the ventral tegmental
area, with DOC/AngII inducing the most immunostaining. In the core and shell, each treatment
condition induces cFos immunostaining compared with vehicle; DOC/AngII induced the highest
amount of immunostaining. Representative images of the ventral tegmental area and nucleus
accumbens (coronal plane, 10x) in each treatment condition are shown above the bar graphs.
Abbreviations: AngII = Angiotensin II, DOC = deoxycorticosterone acetate, NuAcc= Nucleus
Accumbens, Veh = Vehicle, VTA= Ventral Tegmental Area
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Figure 4.3. PVN inactivation enhances AngII-induced cFos expression in the ventral
tegmental area and nucleus accumbens.
Bar graphs illustrating cFos cell counts in the ventral tegmental area and nucleus accumbens
core and shell after either vehicle or lidocaine pretreatment in the PVN followed by icv vehicle or
AngII (n = 12/group). AngII and DOC/AngII treatment increased cFos expression in the ventral
tegmental area, with DOC/AngII further enhancing this activation. In the core and shell, each
treatment condition induces cFos immunostaining compared with vehicle; DOC/AngII further
enhances activation in the core but not the shell. Representative images of the ventral tegmental
area and nucleus accumbens (coronal plane, 10x) in each treatment condition are shown above
the bar graphs. Abbreviations: AngII = Angiotensin II, NuAcc= Nucleus Accumbens, Veh =
Vehicle, VTA= Ventral Tegmental Area
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Figure 4.4. DOC/AngII treatment increases tyrosine hydroxylase activation in the ventral
tegmental area and nucleus accumbens.
Panel A. Bar graphs illustrating tyrosine hydroxylase levels in the ventral tegmental area and
nucleus accumbens (core and shell) after either oil or DOC pretreatment followed by icv
treatments with AngII (n = 3/group). Each treatment increased tyrosine hydroxylase expression
in the ventral tegmental area, but there was only a trend for increased tyrosine hydroxylase
expression in the nucleus accumbens core and shell compared to vehicle. Representative
western blot images of tyrosine hydroxylase are shown above each quantified bar. Panel B. Bar
graphs illustrating phosphorylated tyrosine hydroxylase levels in the ventral tegmental area and
nucleus accumbens (core and shell) after either oil or DOC pretreatment followed by icv
treatments with AngII (n = 3/group).
Only DOC pretreatment significantly increased
phosphorylated tyrosine hydroxylase expression in the ventral tegmental area compared to
vehicle. However, each treatment increased phosphorylated tyrosine hydroxylase expression in
the nucleus accumbens core and shell. Representative western blot images of phosphorylated
tyrosine hydroxylase are shown above each quantified bar. Panel C. Bar graphs illustrating
phosphorylated tyrosine hydroxylase levels normalized to total tyrosine hydroxylase levels in the
ventral tegmental area and nucleus accumbens (core and shell) and after either oil or DOC
pretreatment followed by icv treatments with AngII (n = 3/group). Only DOC/AngII significantly
increased normalized phosphorylated tyrosine hydroxylase expression in the ventral tegmental
area compared to vehicle. However, each treatment increased normalized phosphorylated
tyrosine hydroxylase expression in the nucleus accumbens. Abbreviations: AngII = Angiotensin
II, NuAcc= Nucleus Accumbens, phospho-TH = phosphorylated tyrosine hydroxylase, TH =
tyrosine hydroxylase, Veh = Vehicle, VTA= Ventral Tegmental Area
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CHAPTER 5: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
	
  
Sodium is a necessary part of our diet; we do not crave other minerals in the
same way we desire sodium (Geerling & Loewy, 2008). Sodium appetite is a crucial
participant in fluid balance, which determines one’s fluid volume, blood circulation, and
neuronal function (Andersson, 1977). Not only is this behavior vital to homeostasis, but
also it has been linked to an increased risk of hypertension (Vollmer et al., 2001). Yet,
the biological basis of sodium appetite remains undefined. With this in mind, the goal of
this thesis was to elucidate the cellular signaling and neural circuitry underlying sodium
appetite.
The previous chapters extend our knowledge of the etiology of sodium appetite,
identifying signaling proteins and brain areas required for this behavior. Specifically, in
Chapter 2, I described the role of MAPK signaling in sodium appetite using a preparation
of endogenous AngII production. This signaling protein was found to be specific to
sodium appetite, as its inhibition did not affect thirst or neurohypophyseal secretion.
Following these discoveries, I demonstrated in Chapter 3 that when both aldosterone
and AngII are present, IP3 becomes more important in modulating sodium appetite. We
next examined brain areas important for potentiation of sodium appetite by both
functional neuroanatomy and reversible lesions. Our data supported the hypothesis that
DOC suppresses oxytocin secretion in the PVN, disinhibiting the OVLT for further AngII
activation, and thereby potentiating sodium appetite. Chapter 4 targeted downstream
brain areas involved in aldosterone- and AngII-induced sodium appetite, identifying the
mesolimbic system as another possible integration site for these hormones to augment
the drive for sodium. Together, these experiments determine specific signaling proteins
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and brain sites required for aldosterone and AngII to induce sodium appetite. Below I
discuss the implications and important future directions supported by these studies.

Comparing Sodium Appetite Preparations
As mentioned in the Introduction, different preparations of sodium appetite
diverge in both mechanism and time course for development of the behavior. Taking
this into consideration, it is important to compare and contrast the two preparations I
utilized in my dissertation, as it may better explain my results. In Chapter 2, I
administered the diuretic furosemide, followed by a low dose of the ACE inhibitor
captopril, which increases plasma levels of both aldosterone and AngI (Thunhorst et al.,
1994). The resultant level of plasma aldosterone is high relative to control rats (B. Lu,
Yang, Chen, Yang, & Yan, 2009; Omouessi, Falconetti, Chapleur, Fernette, & Thornton,
2007). However, as aldosterone cannot penetrate the blood brain barrier efficiently, it is
likely that it remains in the plasma to counteract the effect of furosemide on the kidney
(Pardridge & Mietus, 1979). Concurrently, captopril blocks AngI conversion to AngII
peripherally, resulting in nearly ten times more plasma AngI than a control rat, allowing
for maximum conversion to AngII centrally (B. Lu et al., 2009; Thunhorst et al., 1994).
Importantly, my pharmacological data from Chapter 2 supports the key role of central
AngII in this preparation; the central AT1 receptor mediates the majority of the sodium
ingestion these studies.
On the other hand, our DOC/AngII preparation of sodium appetite in Chapter 3
and 4 allows central action of both hormones. Subcutaneous DOC easily crosses the
blood brain barrier due to its structure, giving it access to the hindbrain, where MR and
HSD2 reside (Pardridge & Mietus, 1979). Additionally, this preparation does not cause
natriuresis, so DOC action is not required peripherally. In fact, studies using both
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peripheral and central MR antagonists revealed that central aldosterone is of utmost
importance in this preparation of sodium appetite (Sakai et al., 1986; Sakai et al., 1996).
In contrast to the furo/cap preparation, I administered AngII directly into the lateral
ventricle of the brain, allowing it to act on its type 1 receptors in the forebrain. As the low
doses of each hormone in this preparation are not enough to stimulate sodium appetite
on their own, their interaction is required to elicit such a robust behavior (Epstein, 1982;
Fluharty & Epstein, 1983). To summarize, sodium appetite induced by furo/cap can be
attributed to actions of central AngII, whereas the behavior induced by low doses of
DOC and AngII requires central interaction of both hormones.

Cellular Signaling Underlying Sodium Appetite
The AT1 receptor and MR induce many signaling pathways, but the implications
of MAPK and IP3 have been of recent focus due to their demonstrated behavioral
consequences (Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009; Fleegal &
Sumners, 2003). In agreement with previous findings administering exogenous central
AngII, I found a treatment inducing endogenous AngII utilized MAPK activation to prompt
sodium appetite (Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009; Daniels D, Yee
DK, Faulconbridge LF, Fluharty SJ, 2005; Felgendreger, Fluharty, Yee, & FlanaganCato, 2013b). However, when actions of central aldosterone and AngII were combined,
MAPK was not required for the potentiation of sodium appetite.
These opposing results can be explained pharmacologically or mechanistically.
Pharmacologically, it may be that the dose of the MAPK inhibitor used in the DOC/AngII
studies was simply not high enough to counteract an amplified MAPK signal that arises
when both hormones are present. While furo/cap-induced sodium appetite is attributed
to the AT1R, which may prompt a given level of MAPK signaling, DOC/AngII-induced
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sodium appetite may generate considerably higher levels of MAPK signaling. This could
be due to an upregulation of AT1R induced by DOC pretreatment, non-genomic MR
MAPK signals, or both (Sakai, McEwen, Fluharty, & Ma, 2000; Wilson, Sumners,
Hathaway, & Fregly, 1986). However, the western blot data from Chapter 3 does not
show further AT1R-MAPK activation with DOC pretreatment, so this explanation does
not seem likely. In contrast, DOC pretreatment may induce mechanistic changes that
substitute the role of MAPK. For example, perhaps the normal function of AT1R-MAPK
is to desensitize oxytocin receptors in the OVLT. If DOC inhibits oxytocin release from
the PVN during pretreatment days, oxytocin will not bind to its receptors in the OVLT, so
the actions of MAPK are no longer needed. Future studies should examine the relevant
cellular consequences of MAPK, and determine how DOC may interfere during
pretreatment.
Not only does the interaction of aldosterone and AngII no longer require MAPK
activation, but IP3 signaling contributes to the potentiation of sodium appetite. Another
study negated a role for PKC in exogenous AngII-induced sodium appetite; However, I
did not test the contribution of IP3 signaling in my furo/cap model of sodium appetite,
therefore it cannot be ruled out (Daniels D, Mietlicki EG, Nowak EL, Fluharty SJ, 2009;
Felgendreger et al., 2013). In support of a role for IP3 in sodium appetite, a previous
study used an analog of AngII that only induces AT1R-MAPK signaling, which does not
elicit as much sodium ingestion as AngII itself (Daniels D, Yee DK, Faulconbridge LF,
Fluharty SJ, 2005). Moreover, examination of sodium ingestion data from both Chapter
2 and 3 will reveal that inhibition of either MAPK or IP3 signaling does not completely
ablate the behavior. In effect, these data suggest that neither signaling protein is solely
responsible for the behavior.
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After comparing the role of signaling proteins in two preparations of sodium
appetite, the hypothesis that divergent AT1R signaling causes two separate behaviors is
not well supported. In particular, the role of these signaling proteins changed when
aldosterone and AngII were both elevated. Moreover, these signaling pathways are
ubiquitous in the brain, making it unlikely that their function is specific to these behaviors.
The more apt explanation is that these molecules have specific functions within circuits
underlying thirst and sodium appetite.
Circuits for thirst and sodium appetite overlap in certain brain regions like the
OVLT. It is possible that there are subsets of cells within each brain region that use IP3
or MAPK signaling to contribute to each behavior. However, the subset of cells
important for each behavior may change depending on input from other brain areas in
the circuit, such as when aldosterone is present. My studies suggest that aldosterone
enhances the efficiency of neurons responsive to AngII, negating the need for MAPK
signaling in one subset of cells, and shifting to activation of IP3 in another set of cells to
contribute to the potentiation of sodium appetite. While parenchymal injections of
signaling inhibitors may more clearly delineate where signaling proteins exert their
effects on behavior, targeting subsets of cells within a small region like the OVLT may be
extremely difficult.

Neural Circuitry Underlying Sodium Appetite
Although I did not administer brain region-specific injections of signaling
inhibitors, I did examine protein activation in particular brain areas by both western blot
and immunohistochemistry. This allowed me to identify important brain regions involved
in the circuit underlying sodium appetite. In Chapter 2 and 3, MAPK activation was
induced by furo/cap treatment and icv AngII, respectively, in both the circumventricular
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organs and hypothalamus. Additionally, Chapter 3 revealed increased AngII-induced
cFos, used as a proxy for IP3 signaling, in these same brain areas. However, as AngII
causes two separate behaviors, namely, thirst and sodium appetite, it is difficult to
determine the contribution of these brain regions to sodium appetite alone. To
accomplish this, one would have to correlate brain activation with the effect of sitespecific inhibitors on behavior.

The Oxytocin Disinhibition Hypothesis
Conversely, one could examine brain activation after a treatment that specifically
enhances sodium appetite. Comparing AngII- with DOC/AngII-induced brain activation
gives us the opportunity to distinguish which brain regions play a significant role in
sodium appetite, as DOC pretreatment enhances only sodium appetite and not thirst. In
Chapter 3, DOC plus AngII uniquely enhanced OVLT activation and reduced PVN
activity, suggesting that these brain regions are important in potentiating sodium
appetite. Together with the oxytocin secretion data from Chapter 3, we hypothesized
that DOC suppresses oxytocin in the PVN, disinhibiting the OVLT to induce sodium
appetite. This would suggest that the OVLT contains oxytocin inputs from the PVN,
which is supported by the literature (Buijs, 1978; Kelly & Watts, 1996; Yoshimura et al.,
1993).
However, the OVLT may participate in circuits for both sodium appetite and thirst.
Supporting this concept, infusion of AngII into the OVLT induces both water and sodium
appetite (Fitts et al., 1990). Perhaps within the OVLT, a certain subset of cells is
involved in sodium appetite while another is involved in thirst. Taking our data into
account, the subset of cells receiving oxytocinergic input from the PVN would only be
involved in sodium appetite. I have acquired preliminary data labeling the OVLT with
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oxytocin after hormone treatments to determine the exact location of this subset of cells
(see Figure A.1 in the Appendix). This idea of behavior-specific cell clusters is
reinforced by previous studies lesioning the OVLT, which reveal different behavioral
consequences depending on the size and location of the cut (Johnson & Thunhorst,
1997). In particular, lesioning cells with oxytocin input from the PVN would enhance
sodium appetite, while destroying thirst or sodium appetite cells projecting downstream
would abrogate one or both behaviors. Further studies could classify locations of these
cell clusters within the OVLT after different hormone treatments to determine which are
important for thirst versus sodium appetite (Miller, Wang, Gray, Salkoff, & Loewy, 2013).
Beyond correlating brain activation, I used a reversible lesion to causally link
PVN inactivation and enhanced AngII-induced sodium appetite. I aimed to mimic the
actions of DOC in this experiment, but some key differences should be discussed.
Administration of lidocaine into the PVN globally inactivates action potentials in all cells
within the PVN, while DOC most likely targets the magnocellular oxytocin secreting
neurons. Therefore, it is possible that lidocaine may inhibit other PVN neuronal
phenotypes, such as preautonomic or vasopressinergic neurons, but as water intake
was unaffected, this is improbable. As a separate concern, the dose of lidocaine given
was based on studies examining pressor responses, and may or may not completely
inactivate all PVN neurons (Fernandes et al., 2007; Flanagan et al., 1992). Failure to
completely inactivate these PVN neurons might explain why sodium appetite was not as
robust compared to when DOC and AngII work together. On the other hand, perhaps
DOC has additional functions besides inhibiting oxytocin release, so recreating only one
of these functions in the lidocaine experiment does not fully potentiate sodium appetite.
Future experiments targeting inhibition of only the magnocellular oxytocin neurons,
perhaps with optogenetics, may help clarify which of these possibilities is true.
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The path by which aldosterone may influence PVN oxytocin secretion remains
undefined, though some tracing studies identify the bed nucleus stria terminalis (BNST)
as the main candidate to transfer information from the NTS to the PVN (Geerling &
Loewy, 2009). The BNST contains GABAergic neurons that may receive input from the
NTS and project to the PVN, allowing for inhibition of oxytocin (Cullinan et al., 1993;
Dong et al., 2001). Preliminary data examining cFos activation revealed that DOC
increases BNST activity (See Figure A.2 in the Appendix). This would suggest that the
BNST is active when DOC is present, possibly sending an inhibitory signal to the PVN to
prevent oxytocin secretion. A more telling future experiment to determine these
connections would involve injecting a retrograde tracer into the PVN and an anterograde
tracer into the NTS and examining if they colocalize in the BNST.

Mesolimbic Activity Underlying Sodium Appetite
Upon discerning some of the forebrain regions important for sodium appetite, it
was logical to next examine brain regions that may be further downstream in the circuit
leading to a robust sodium appetite. The mesolimbic dopamine system, thought to be
involved in natural reward, was a good candidate for investigation. Chapter 4
demonstrated that the combination of DOC plus AngII resulted in a selective motivation
for sodium compared to water. However, DOC pretreatment only slightly enhanced
presses for sodium compared to AngII alone. Perhaps the doses of DOC and AngII
administered were only capable of stimulating the demonstrated amount of work for such
a highly concentrated saline solution, hitting a “ceiling”. Using a less concentrated saline
reward in the progressive ratio experiment could test this idea. Nevertheless, the
amount of 3% saline ingested in these studies was not sufficient to satisfy the daily
requirement for salt. In addition, the number of presses over time did not approach the
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limits of what is physically possible. Regardless, I think the most interesting data is not
the total presses for saline, but the shift from pressing water to saline when both
hormones are present. One cannot visualize this shift in behavior in Chapter 3 because
the intake data is reported at final time points. Differential circuit activation undoubtedly
underlies this shift in behavior.
Although the combination of DOC plus AngII induces a selective drive for
sodium, it is mainly AngII treatment that induces cFos activation in the VTA and nucleus
accumbens. It is possible that cFos expression is not a good measure of DOC effects
for two reasons: 1) injections of DOC are given for days in advance, and not perfectly
timed to maximal cFos expression (Sagar et al., 1988) and 2) the dose of DOC given is
too low to induce cFos expression (Pietranera et al., 2001). However, DOC and AngII
potentiation of cFos expression was seen in the OVLT in Chapter 3, discrediting these
possibilities. Similar to the number of sodium presses, DOC/AngII-cFos activation is not
significantly different from AngII alone. This, too, might be a result of a “ceiling”, as the
images of these brain areas show very intense cFos staining; it is feasible that the
maximum number of cells are activated in this condition. In contrast with the behavior,
we have only captured a snapshot of cell activation at one time point. Compared to
AngII treatment, we can attribute additional activated cells to motivation for sodium in the
combined hormone treatment, but concentrated nuclear staining makes this difficult.
Activity in these mesolimbic areas likely indicates motivation for both water and sodium;
Though DOC/AngII potentiates sodium intake, it also reduces water intake, so the total
activation in this brain region may not be further enhanced compared to AngII alone. It
might be informative to use treatments that induce only one behavior and examine the
pattern of activation in these brain areas, possibly identifying subregions of behavioral
specificity.
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In contrast to DOC/AngII administration, lidocaine injected into the PVN in
combination with icv AngII enhanced mesolimbic activation. This negates the idea that
there is a “ceiling” for cFos activation in mesolimbic areas after DOC/AngII treatment.
Additionally, this indicates that lidocaine/AngII enhancement of sodium appetite does not
in fact mimic that of DOC/AngII treatment. On the other hand, the lidocaine/AngII data
does indicate that rapid inactivation of the PVN enhances mesolimbic activation, similar
to its effects on the OVLT in Chapter 3. Though the lateral hypothalamus is the most
likely candidate for transfer of information between the OVLT and VTA, I did not validate
this in my experiments (Camacho & Phillips, 1981; Fadel & Deutch, 2002). This would
be an important brain area to examine in future studies in order to have a more complete
picture of the circuit underling sodium appetite. While cFos activation in the lateral
hypothalamus after these treatments would be an important first step, tracing studies
would provide a more elegant demonstration of connections within this part of the circuit
for sodium appetite.
In accordance with previous literature, our preparation of sodium appetite was
associated with an increase in markers of dopamine synthesis, indicating the anticipation
of a reward (Roitman, Schafe, Thiele, & Bernstein, 1997; Sunsay & Rebec, 2008).
Specifically, aldosterone increased tyrosine hydroxylase expression in the ventral
tegmental area and accumbens. Aldosterone was injected for three days before
collecting tissue, a time frame conducive to gene transcription. However, AngII
increased tyrosine hydroxylase expression within five minutes in the ventral tegmental
area, which is in accordance with previous studies (Liang et al., 2012). This rapid
increase in tyrosine hydroxylase immunoreactivity may be due to: 1) translation of
preexisting mRNA or 2) a change in location or conformation of the protein that allows it
to become immunoreactive following hormone treatment (Cao et al., 1996). Future
	
  
115	
  
	
  

experiments could inspect tyrosine hydroxylase mRNA after different treatments,
including acute injections of DOC, to determine how these dynamic changes take place.
Aldosterone also increased tyrosine hydroxylase phosphorylation, which would
allow the enzyme to synthesize more dopamine, possibly enhancing motivation for
sodium. However, DOC treatment alone does not induce much sodium appetite, yet
marked increases in tyrosine hydroxylase activity were still observed. As a result, the
correlation between VTA tyrosine hydroxylase levels and sodium intake is weak (See
Figure A.3 in the Appendix). Nevertheless, DOC did induce water intake in our
progressive ratio studies, and as tyrosine hydroxylase activity would not discern between
motivation for water versus sodium, this may explain the disconnect. In contrast, the
correlation between OVLT activity and VTA tyrosine hydroxylase is strong, supporting
the idea that OVLT activity dictates downstream dopamine activity in the VTA. This
makes sense considering both brain areas are involved in thirst and sodium appetite, so
total activation levels are more likely to correlate. While tyrosine hydroxylase expression
indicates increased dopamine activity in sodium appetite, measuring dopamine levels
through microdialysis in real time would reveal much more detailed information on how
mesolimbic activity is affected during dynamic changes in motivation for sodium.

Thesis Contributions and the Future of Sodium Appetite
These studies advance our understanding of the central pathways controlling
sodium appetite, a behavior that is integral to our survival. I have identified signaling
proteins involved in the regulation of aldosterone- and AngII-induced sodium appetite,
but more importantly, revealed key brain areas and possible connections within the
circuitry underlying the potentiation of sodium appetite. In particular, my studies have
demonstrated that aldosterone relieves an inhibitory oxytocin signal from the PVN to the
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OVLT to enhance sodium appetite. Preliminary data suggests aldosterone may
inactivate oxytocin release through the BNST. In addition, my data suggest AngII and
aldosterone actions converge on the VTA to enhance sodium appetite. Nevertheless,
much work remains in delineating the complete circuit responsible for sodium appetite.
This would include tracing studies that show clear connections as demonstrated in the
diagram below (Figure 5.1). Moreover, it would be beneficial to perform optogenetic
studies activating or inactivating these key connections and observing the presence or
absence of the behavior. Lastly, it should be pointed out that this circuitry model of
sodium appetite is oversimplified, as there are other excitatory and inhibitory systems
underlying sodium appetite. Regardless, this thesis provides advances in understanding
this crucial behavior.
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Figure 5.1. Model Circuit Diagram for Aldosterone- and AngII-induced Sodium Appetite
Pictured above is a model circuit diagram explaining proposed connections in aldosterone- and
AngII-induced sodium appetite. Connections pictured in black have been established by my
data and previous literature. Brain areas in gray are expected connections between the
regions in black, based on my preliminary data and previous literature. Dotted lines indicate
multiple synaptic connections leading to expression of the behavior. Abbreviations: AngII =
Angiotensin II, BNST = Bed Nucleus Stria Terminalis, DA = Dopamine, DOC=
Deoxycorticosterone Acetate, H2O = Populations of cells responsive to signals for water intake
+
(thirst), LH = Lateral Hypothalamus, Na = Populations of cells responsive to signals for
sodium intake (sodium appetite), NuAcc = Nucleus Accumbens, NTS = Nucleus of the Solitary
Tract, OT= oxytocin, OVLT = Organum Vasculosum Lateral Terminalis, PVN = Paraventricular
Nucleus of the Hypothalamus, SFO = Subfornical Organ, VTA = Ventral Tegmental Area
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APPENDIX

	
  
Figure A.1. AngII-induced oxytocin staining in the OVLT is reduced by DOC pretreatment.
Bar graphs illustrating the optical density for oxytocin immunohistochemical staining in the OVLT
after Vehicle, DOC, AngII, or DOC/AngII treatment (n = 3/group). Representative images of
oxytocin staining of OVLT coronal sections (10x) in each treatment are shown above the graphs.
AngII induced significant oxytocin staining, which was reduced by DOC pretreatment.
Abbreviations: AngII = Angiotensin II, DOC = Deoxycorticosterone Acetate
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Figure A.2. DOC increases cFos activation in the BNST.
Bar graphs illustrating cFos staining in the OVLT after Vehicle, DOC, AngII, or DOC/AngII
treatment (n = 5-6/group). Representative images of cFos staining of OVLT coronal sections
(10x) in each treatment are shown above the graphs. DOC increased cFos staining in the OVLT,
regardless of icv treatment. Abbreviations: AngII = Angiotensin II, DOC = Deoxycorticosterone
Acetate
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Figure A.3. Tyrosine Hydroxylase in the Ventral Tegmental Area correlates with cFos in the
OVLT, but not sodium intake.
Correlations of VTA Tyrosine Hydroxylase with both Sodium Intake (left) and cFos in the OVLT
(right) after Vehicle, DOC, AngII, and DOC/AngII treatments. Tyrosine Hydroxylase levels have a
weak correlation with sodium intake, but a strong correlation with OVLT cFos. Abbreviations:
AngII = Angiotensin II, DOC = Deoxycorticosterone Acetate, TH = tyrosine hydroxylase, VTA =
ventral tegmental area
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